

The landscape of cancer genes and mutational processes

Nature

486, 400-404

DOI: [10.1038/nature11017](https://doi.org/10.1038/nature11017)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Role of the Brainstem in Blood Pressure Regulation in the Dog. <i>Neurology</i> , 1954, 4, 1-1.	1.5	28
2	Theoretical Analysis of Gas Breakdown Characteristic through a Narrow Discharge Tube. <i>Japanese Journal of Applied Physics</i> , 1995, 34, 3671-3674.	0.8	7
3	BINARY STARS WITH COMPONENTS OF SOLAR TYPE: 25 ORBITS AND SYSTEM MASSES. <i>Astronomical Journal</i> , 2009, 138, 1159-1170.	1.9	16
4	Five-dimensional teleparallel theory equivalent to general relativity, the axially symmetric solution, energy and spatial momentum. <i>Chinese Physics B</i> , 2011, 20, 110402.	0.7	0
5	A 2D nonlinear inversion of well-seismic data. <i>Inverse Problems</i> , 2011, 27, 055005.	1.0	5
6	Next-generation sequencing in breast cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 597-604.	1.1	76
7	Genomic analysis and selected molecular pathways in rare cancers. <i>Physical Biology</i> , 2012, 9, 065004.	0.8	8
8	Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes. <i>Genes and Cancer</i> , 2012, 3, 550-563.	0.6	20
9	Genome-based diagnostics and predictive tools: a new epoch for breast cancer management. <i>Future Oncology</i> , 2012, 8, 1211-1214.	1.1	0
10	New light on p27 ^{kip1} in breast cancer. <i>Cell Cycle</i> , 2012, 11, 3701-3702.	1.3	18
11	SWI/SNF complex in disorder. <i>Epigenetics</i> , 2012, 7, 1219-1224.	1.3	70
12	Disrupting cancer cells' biocircuits with interactome-based drugs: is "clinical" innovation realistic?. <i>Expert Review of Proteomics</i> , 2012, 9, 349-353.	1.3	20
13	Assessing tumor heterogeneity and emergence mutations using next-generation sequencing for overcoming cancer drugs resistance. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1245-1248.	1.1	9
14	Next-generation sequencing-based testing for cancer mutational landscape diversity: clinical implications?. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 667-670.	1.5	3
15	Imaging as a potential tool for subtyping breast cancer. <i>Imaging in Medicine</i> , 2012, 4, 577-579.	0.0	0
16	Molecular Pathology of Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2012, 138, 770-780.	0.4	91
17	Cancer genomics and pathology: All Together Now. <i>Pathology International</i> , 2012, 62, 647-659.	0.6	6
18	AIDing the immune system "DIAbolic in cancer. <i>Seminars in Immunology</i> , 2012, 24, 241-245.	2.7	21

#	ARTICLE	IF	CITATIONS
19	Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. Breast Cancer Research, 2012, 14, 322.	2.2	1
20	Who's driving anyway? Herculean efforts to identify the drivers of breast cancer. Breast Cancer Research, 2012, 14, 323.	2.2	8
21	Bioinformatics for cancer immunology and immunotherapy. Cancer Immunology, Immunotherapy, 2012, 61, 1885-1903.	2.0	40
23	Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?. Critical Reviews in Oncology/Hematology, 2012, 84, e58-e69.	2.0	10
24	What are we learning from the cancer genome?. Nature Reviews Clinical Oncology, 2012, 9, 621-630.	12.5	50
25	SnapShot: Breast Cancer. Cancer Cell, 2012, 22, 562-562.e1.	7.7	64
26	Biomarker Discovery in Penile Cancer. Journal of Urology, 2012, 188, 1660-1661.	0.2	2
27	Breast Cancer Heterogeneity: Need to Review Current Treatment Strategies. Current Breast Cancer Reports, 2012, 4, 225-231.	0.5	3
28	Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (<i>NF1</i>) as a Breast Cancer Driver. Genetics, 2012, 192, 385-396.	1.2	61
29	Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. Genome Medicine, 2012, 4, 89.	3.6	91
30	Inferring novel gene-disease associations using Medical Subject Heading Over-representation Profiles. Genome Medicine, 2012, 4, 75.	3.6	25
31	Mutational Processes Molding the Genomes of 21 Breast Cancers. Cell, 2012, 149, 979-993.	13.5	1,673
32	The breast cancer landscape. Nature, 2012, 486, 328-329.	13.7	32
33	Embryonic mammary signature subsets are activated in Brca1 -/- and basal-like breast cancers. Breast Cancer Research, 2013, 15, R25.	2.2	52
34	Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Research, 2013, 15, R8.	2.2	61
35	The T-box Transcription Factors TBX2 and TBX3 in Mammary Gland Development and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2013, 18, 143-147.	1.0	58
36	Functional diversity and pharmacological profiles of the FKBP and their complexes with small natural ligands. Cellular and Molecular Life Sciences, 2013, 70, 3243-3275.	2.4	37
37	Cancer heterogeneityâ€”a multifaceted view. EMBO Reports, 2013, 14, 686-695.	2.0	208

#	ARTICLE	IF	CITATIONS
38	Cancer Genomics. , 2013, , .		4
39	Evidence for APOBEC3B mutagenesis in multiple human cancers. Nature Genetics, 2013, 45, 977-983.	9.4	660
40	Breast cancer as a systemic disease: a view of metastasis. Journal of Internal Medicine, 2013, 274, 113-126.	2.7	546
41	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	9.4	674
42	Next generation sequencing in cancer research and clinical application. Biological Procedures Online, 2013, 15, 4.	1.4	102
43	CoNVEX: copy number variation estimation in exome sequencing data using HMM. BMC Bioinformatics, 2013, 14, S2.	1.2	61
44	Assessment of computational methods for predicting the effects of missense mutations in human cancers. BMC Genomics, 2013, 14, S7.	1.2	153
45	Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. BMC Genomics, 2013, 14, 165.	1.2	33
46	Luminal breast cancer: from biology to treatment. Nature Reviews Clinical Oncology, 2013, 10, 494-506.	12.5	183
47	Next generation analysis of breast cancer genomes for precision medicine. Cancer Letters, 2013, 339, 1-7.	3.2	19
48	A new genome-driven integrated classification of breast cancer and its implications. EMBO Journal, 2013, 32, 617-628.	3.5	267
49	Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nature Genetics, 2013, 45, 923-926.	9.4	180
50	Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis. Laboratory Investigation, 2013, 93, 701-710.	1.7	26
51	Personalized therapy for breast cancer: a dream or a reality?. Future Oncology, 2013, 9, 1105-1119.	1.1	27
52	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	13.7	8,060
53	Deciphering Signatures of Mutational Processes Operative in Human Cancer. Cell Reports, 2013, 3, 246-259.	2.9	1,087
54	Inherited Genetic Susceptibility to Breast Cancer. American Journal of Pathology, 2013, 183, 1038-1051.	1.9	82
55	Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Laboratory Investigation, 2013, 93, 970-982.	1.7	163

#	ARTICLE	IF	CITATIONS
56	Triple-Negative Breast Cancer and the Need for New Therapeutic Targets. American Journal of Pathology, 2013, 183, 1064-1074.	1.9	135
57	Beyond <i>BRCA1/2</i> : polygenic, "polyfunctional"™ molecular circuitry model to predict breast cancer risk. Biomarkers in Medicine, 2013, 7, 675-678.	0.6	2
58	PIK3CA-AKT pathway mutations in micropapillary breast carcinoma. Human Pathology, 2013, 44, 1320-1327.	1.1	17
59	Mutational analysis of breast cancer: Guiding personalized treatments. Breast, 2013, 22, S19-S21.	0.9	16
60	Differences that matter in cancer genomics. Nature Biotechnology, 2013, 31, 892-893.	9.4	3
61	DGIdb: mining the druggable genome. Nature Methods, 2013, 10, 1209-1210.	9.0	443
62	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 2013, 31, 1023-1031.	9.4	1,785
63	From Integrative Genomics to Therapeutic Targets. Cancer Research, 2013, 73, 3483-3488.	0.4	19
64	Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers. Clinical Cancer Research, 2013, 19, 3738-3744.	3.2	53
65	Recruitment of NCOR1 to VDR target genes is enhanced in prostate cancer cells and associates with altered DNA methylation patterns. Carcinogenesis, 2013, 34, 248-256.	1.3	50
66	Cancer Genome Landscapes. Science, 2013, 339, 1546-1558.	6.0	6,507
67	Cell and Molecular Biology of Breast Cancer. , 2013, , .		10
68	MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. Genes and Cancer, 2013, 4, 419-426.	0.6	99
69	PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines. Clinical Cancer Research, 2013, 19, 3533-3544.	3.2	122
70	The molecular diversity of Luminal A breast tumors. Breast Cancer Research and Treatment, 2013, 141, 409-420.	1.1	120
71	Molecular Profiling of Human Mammary Gland Links Breast Cancer Risk to a p27+ Cell Population with Progenitor Characteristics. Cell Stem Cell, 2013, 13, 117-130.	5.2	72
72	The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 2013, 501, 338-345.	13.7	1,969
74	Nuclear Mechanics and Mechanotransduction in Health and Disease. Current Biology, 2013, 23, R1113-R1121.	1.8	297

#	ARTICLE	IF	CITATIONS
75	Can Unknown Predisposition in Familial Breast Cancer be Family-Specific?. Breast Journal, 2013, 19, n/a-n/a.	0.4	26
76	Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i> . New England Journal of Medicine, 2013, 369, 2391-2405.	13.9	1,556
77	Integration of Gene Signatures and Genomic Data into Radiation Oncology Practice. Medical Radiology, 2013, , 29-46.	0.0	0
78	Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Breast Cancer Research, 2013, 15, R66.	2.2	74
80	Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2013, 142, 81-88.	1.1	3
81	Emerging patterns of somatic mutations in cancer. Nature Reviews Genetics, 2013, 14, 703-718.	7.7	442
82	Genetically engineered mouse models of PI3K signaling in breast cancer. Molecular Oncology, 2013, 7, 146-164.	2.1	34
83	p120-catenin in cancer – mechanisms, models and opportunities for intervention. Journal of Cell Science, 2013, 126, 3515-3525.	1.2	75
84	Deep sequencing and integrative genome analysis: approaching a new class of biomarkers and therapeutic targets for breast cancer. Pharmacogenomics, 2013, 14, 5-8.	0.6	3
85	A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells. Cancer Cell, 2013, 24, 182-196.	7.7	147
86	Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine. American Journal of Pathology, 2013, 183, 1052-1063.	1.9	75
87	Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway. Surgical Oncology Clinics of North America, 2013, 22, 641-664.	0.6	161
88	Germline BAP1 Mutations Predispose to Renal Cell Carcinomas. American Journal of Human Genetics, 2013, 92, 974-980.	2.6	239
89	Coffin-Siris Syndrome and the BAF Complex: Genotype-Phenotype Study in 63 Patients. Human Mutation, 2013, 34, 1519-1528.	1.1	178
90	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nature Genetics, 2013, 45, 1483-1486.	9.4	275
91	The classification of invasive carcinoma of the breast. Expert Review of Anticancer Therapy, 2013, 13, 941-954.	1.1	14
93	Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the <i>RAS</i> pathway, but no <i>KIT</i> mutations. Histopathology, 2013, 62, 543-550.	1.6	39
94	Needles in a haystack: finding recurrent genomic changes in breast cancer. Breast Cancer Research, 2013, 14, 304.	2.2	2

#	ARTICLE	IF	CITATIONS
95	Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression. Breast Cancer Research, 2013, 15, 309.	2.2	1
96	The genomic map of breast cancer: which roads lead to better targeted therapies?. Breast Cancer Research, 2013, 15, 209.	2.2	10
97	Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 2013, 122, 3616-3627.	0.6	1,562
98	Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. Cancer Discovery, 2013, 3, 224-237.	7.7	697
99	Genomic Medicine: New Frontiers and New Challenges. Clinical Chemistry, 2013, 59, 158-167.	1.5	59
100	Reflections on the Founding of the International Cancer Genome Consortium. Clinical Chemistry, 2013, 59, 18-21.	1.5	5
101	Mutational analysis of splicing machinery genes <sc><i>SF3B1, U2AF1</i></sc> and <sc><i>SRSF2</i></sc> in myelodysplasia and other common tumors. International Journal of Cancer, 2013, 133, 260-265.	2.3	64
102	The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap. Cancer Discovery, 2013, 3, 27-34.	7.7	200
103	<i>ARID1A</i> Mutations in Cancer: Another Epigenetic Tumor Suppressor?. Cancer Discovery, 2013, 3, 35-43.	7.7	347
104	Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Research and Treatment, 2013, 137, 407-416.	1.1	30
105	Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Research and Treatment, 2013, 137, 449-455.	1.1	38
106	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Cell, 2013, 152, 714-726.	13.5	1,202
107	Acquired Mutations That Affect Pre-mRNA Splicing in Hematologic Malignancies and Solid Tumors. Journal of the National Cancer Institute, 2013, 105, 1540-1549.	3.0	69
108	Rhabdoid Tumors: An Initial Clue to the Role of Chromatin Remodeling in Cancer. Brain Pathology, 2013, 23, 200-205.	2.1	25
109	Signaling Network Assessment of Mutations and Copy Number Variations Predict Breast Cancer Subtype-Specific Drug Targets. Cell Reports, 2013, 5, 216-223.	2.9	106
110	Functional analysisâ€”Make or break for cancer predictability. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2013, 743-744, 132-141.	0.4	6
111	Interpretation, Stratification and Evidence for Sequence Variants Affecting mRNA Splicing in Complete Human Genome Sequences. Genomics, Proteomics and Bioinformatics, 2013, 11, 77-85.	3.0	29
112	Rationale and clinical use of multitargeting anticancer agents. Current Opinion in Pharmacology, 2013, 13, 536-542.	1.7	29

#	ARTICLE	IF	CITATIONS
113	Cancer genome sequencing: Understanding malignancy as a disease of the genome, its conformation, and its evolution. <i>Cancer Letters</i> , 2013, 340, 152-160.	3.2	21
114	Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges. <i>Pharmacogenomics Journal</i> , 2013, 13, 205-208.	0.9	4
115	Hormones and AID: Balancing immunity and autoimmunity. <i>Autoimmunity</i> , 2013, 46, 128-137.	1.2	31
116	Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1199-1209.	13.9	1,884
117	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. <i>Nature Genetics</i> , 2013, 45, 12-17.	9.4	374
118	Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. <i>Cell Cycle</i> , 2013, 12, 762-772.	1.3	127
119	APOBEC3B is an enzymatic source of mutation in breast cancer. <i>Nature</i> , 2013, 494, 366-370.	13.7	758
120	Translating Genomics to the Clinic: Implications of Cancer Heterogeneity. <i>Clinical Chemistry</i> , 2013, 59, 127-137.	1.5	25
121	Emerging targeted agents in metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 191-210.	12.5	158
122	GATA3 Mutations Found in Breast Cancers May Be Associated with Aberrant Nuclear Localization, Reduced Transactivation and Cell Invasiveness. <i>Hormones and Cancer</i> , 2013, 4, 123-139.	4.9	28
123	FOXA1 mutations in hormone-dependent cancers. <i>Frontiers in Oncology</i> , 2013, 3, 20.	1.3	50
124	Lessons from the Cancer Genome. <i>Cell</i> , 2013, 153, 17-37.	13.5	1,133
125	Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma <i>in situ</i> . <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 151-165.	1.5	40
126	Journeys into the genome of cancer cells. <i>EMBO Molecular Medicine</i> , 2013, 5, 169-172.	3.3	27
127	Understanding genomic alterations in cancer genomes using an integrative network approach. <i>Cancer Letters</i> , 2013, 340, 261-269.	3.2	70
128	Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 935-946.	3.4	308
129	End-joining, translocations and cancer. <i>Nature Reviews Cancer</i> , 2013, 13, 443-454.	12.8	311
130	Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. <i>Nature Reviews Cancer</i> , 2013, 13, 497-510.	12.8	490

#	ARTICLE	IF	CITATIONS
131	Mutational heterogeneity in cancer and the search for new cancer-associated genes. <i>Nature</i> , 2013, 499, 214-218.	13.7	4,761
132	Oncogenic ERBB3 Mutations in Human Cancers. <i>Cancer Cell</i> , 2013, 23, 603-617.	7.7	318
133	Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. <i>Nature Genetics</i> , 2013, 45, 592-601.	9.4	1,082
134	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 377-389.	12.5	164
135	Dissecting Disease Inheritance Modes in a Three-Dimensional Protein Network Challenges the “Guilt-by-Association” Principle. <i>American Journal of Human Genetics</i> , 2013, 93, 78-89.	2.6	44
136	Genetic heterogeneity in breast cancer: the road to personalized medicine?. <i>BMC Medicine</i> , 2013, 11, 151.	2.3	47
137	Molecular cytogenetics: recent developments and applications in cancer. <i>Clinical Genetics</i> , 2013, 84, 315-325.	1.0	26
138	PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells. <i>Cancer Cell</i> , 2013, 23, 753-767.	7.7	56
139	Genomics-Driven Oncology: Framework for an Emerging Paradigm. <i>Journal of Clinical Oncology</i> , 2013, 31, 1806-1814.	0.8	315
140	High-Throughput Gene Expression and Mutation Profiling: Current Methods and Future Perspectives. <i>Breast Care</i> , 2013, 8, 401-406.	0.8	14
142	Metasignatures Identify Two Major Subtypes of Breast Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-10.	1.3	17
143	Notch: evidence for combining therapies to treat breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 481-488.	0.2	1
145	ABCs of genomics. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 316-323.	0.9	7
146	Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. <i>Carcinogenesis</i> , 2013, 34, 1520-1528.	1.3	26
148	Integrated clinical genomics: new horizon for diagnostic and biomarker discoveries in cancer. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 1-4.	1.5	9
149	ANTXR1, a Stem Cell-Enriched Functional Biomarker, Connects Collagen Signaling to Cancer Stem-like Cells and Metastasis in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 5821-5833.	0.4	104
150	Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling. <i>PLoS Computational Biology</i> , 2013, 9, e1003047.	1.5	76
151	An evolutionary perspective on anti-tumor immunity. <i>Frontiers in Oncology</i> , 2012, 2, 202.	1.3	15

#	ARTICLE	IF	CITATIONS
152	Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. <i>Annals of Oncology</i> , 2013, 24, 1956-1957.	0.6	21
153	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 1.	0.4	10
154	NRMT2 is an N-terminal monomethylase that primes for its homologue NRMT1. <i>Biochemical Journal</i> , 2013, 456, 453-462.	1.7	42
155	Simultaneous Identification of Multiple Driver Pathways in Cancer. <i>PLoS Computational Biology</i> , 2013, 9, e1003054.	1.5	231
156	Frequent PIK3CA Mutations in Radial Scars. <i>Diagnostic Molecular Pathology</i> , 2013, 22, 210-214.	2.1	19
157	Research and clinical applications of cancer genome sequencing. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 3-10.	0.9	14
158	Issues in clinical research for metastatic breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 625-629.	1.1	7
159	Advances in the treatment of luminal breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 49-54.	0.9	16
161	Tumours associated with BAP1 mutations. <i>Pathology</i> , 2013, 45, 116-126.	0.3	242
162	Targeted therapies of solid cancers. <i>Current Opinion in Oncology</i> , 2013, 25, 296-304.	1.1	21
163	PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System. <i>Clinical Cancer Research</i> , 2013, 19, 5413-5422.	3.2	84
165	Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 960-967.	3.0	138
167	Breast Cancer Genomics: From Portraits to Landscapes. , 2013, , 255-294.		0
168	Does Microenvironment Contribute to the Etiology of Estrogen Receptor–Negative Breast Cancer?. <i>Clinical Cancer Research</i> , 2013, 19, 541-548.	3.2	26
169	The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. <i>Genome Biology</i> , 2013, 14, r106.	13.9	102
170	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2 V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	7.7	43
171	Breed-Predispositions to Cancer in Pedigree Dogs. <i>ISRN Veterinary Science</i> , 2013, 2013, 1-23.	1.1	205
172	Cake: a bioinformatics pipeline for the integrated analysis of somatic variants in cancer genomes. <i>Bioinformatics</i> , 2013, 29, 2208-2210.	1.8	29

#	ARTICLE	IF	CITATIONS
173	Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. <i>Frontiers in Oncology</i> , 2013, 3, 129.	1.3	73
174	Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8. <i>Cancer Research</i> , 2013, 73, 3470-3480.	0.4	342
175	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 169-181.	1.4	149
176	the 11q13-q14 amplicon: Clinicopathological correlations and potential drivers. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 333-355.	1.5	70
177	Functional genomics lead to new therapies in follicular lymphoma. <i>Annals of the New York Academy of Sciences</i> , 2013, 1293, 18-24.	1.8	4
178	Functional and cancer genomics of ASXL family members. <i>British Journal of Cancer</i> , 2013, 109, 299-306.	2.9	123
179	Will Early Detection for Breast Cancer Ever Work?. <i>Clinical Chemistry</i> , 2013, 59, 190-193.	1.5	4
180	Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer. <i>Science Translational Medicine</i> , 2013, 5, 181re1.	5.8	108
181	Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 5-8.	1.1	11
183	Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. <i>Journal of Clinical Oncology</i> , 2013, 31, 1874-1884.	0.8	101
184	Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. <i>Nature Genetics</i> , 2013, 45, 1479-1482.	9.4	667
185	Triple-negative breast cancer: molecular characterization and targeted therapies. <i>Breast Cancer Management</i> , 2013, 2, 417-430.	0.2	1
187	Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1999-2004.	3.3	348
188	Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7413-7417.	3.3	149
189	Incorporating Genomics into Breast Cancer Clinical Trials and Care. <i>Clinical Cancer Research</i> , 2013, 19, 6371-6379.	3.2	15
190	Identification and Selective Degradation of Neopeptide-Containing Truncated Mutant Proteins in the Tumors with High Microsatellite Instability. <i>Clinical Cancer Research</i> , 2013, 19, 3369-3382.	3.2	24
191	Inactivating Mutations in SWI/SNF Chromatin Remodeling Genes in Human Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 849-855.	0.6	56
195	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R97.	2.2	17

#	ARTICLE	IF	CITATIONS
196	Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 174-182.	2.3	44
197	The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models. Genome Biology, 2013, 14, R113.	13.9	40
198	The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 670-678.	2.3	96
199	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. American Journal of Surgical Pathology, 2013, 37, e1-e11.	2.1	137
200	Functional Polymorphisms in Xenobiotic Metabolizing Enzymes and Their Impact on the Therapy of Breast Cancer. Frontiers in Genetics, 2013, 3, 329.	1.1	8
201	Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-7.	1.3	27
202	Identifying potential cancer driver genes by genomic data integration. Scientific Reports, 2013, 3, 3538.	1.6	60
203	Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. OncoTargets and Therapy, 2013, 6, 839.	1.0	95
204	Real-Time Motion Analysis Reveals Cell Directionality as an Indicator of Breast Cancer Progression. PLoS ONE, 2013, 8, e58859.	1.1	50
205	Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis. PLoS ONE, 2013, 8, e62451.	1.1	27
206	A Comparison of 100 Human Genes Using an Alu Element-Based Instability Model. PLoS ONE, 2013, 8, e65188.	1.1	18
207	Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes. PLoS ONE, 2013, 8, e69008.	1.1	148
208	Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer. Journal of Oncology, 2013, 2013, 1-8.	0.6	15
210	Evolvement of microRNAs as Therapeutic Targets for Malignant Gliomas. , 0, , .		1
211	Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers. PLoS ONE, 2014, 9, e88401.	1.1	30
212	Candidate Luminal B Breast Cancer Genes Identified by Genome, Gene Expression and DNA Methylation Profiling. PLoS ONE, 2014, 9, e81843.	1.1	53
213	A Meta-Analysis of Multiple Matched Copy Number and Transcriptomics Data Sets for Inferring Gene Regulatory Relationships. PLoS ONE, 2014, 9, e105522.	1.1	9
214	The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy. PLoS ONE, 2014, 9, e109611.	1.1	24

#	ARTICLE	IF	CITATIONS
215	Nifedipine Promotes the Proliferation and Migration of Breast Cancer Cells. PLoS ONE, 2014, 9, e113649.	1.1	31
216	Deciphering cancer heterogeneity: the biological space. Frontiers in Cell and Developmental Biology, 2014, 2, 12.	1.8	12
217	Somatic Mosaicism in the Human Genome. Genes, 2014, 5, 1064-1094.	1.0	122
218	MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. ELife, 2014, 3, e01763.	2.8	104
219	Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. ELife, 2014, 3, .	2.8	115
220	Mechanisms of Base Substitution Mutagenesis in Cancer Genomes. Genes, 2014, 5, 108-146.	1.0	49
221	Expression of DNA Cytosine Deaminase APOBEC3 Proteins, a Potential Source for Producing Mutations, in Gastric, Colorectal and Prostate Cancers. Tumori, 2014, 100, e112-e117.	0.6	10
222	Next Generation Sequencing in the National Health Service England: A Pipeline that Completely Agrees with Sanger. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	0
225	SWI/SNF Chromatin Remodeling Enzymes in Melanocyte Differentiation and Melanoma. Critical Reviews in Eukaryotic Gene Expression, 2014, 24, 151-161.	0.4	21
226	Subtyping of breast cancer using reverse phase protein arrays. Expert Review of Proteomics, 2014, 11, 757-770.	1.3	17
227	Mislocalization of the Cell Polarity Protein Scribble Promotes Mammary Tumorigenesis and Is Associated with Basal Breast Cancer. Cancer Research, 2014, 74, 3180-3194.	0.4	97
228	Insights into cancer biology through next-generation sequencing. Clinical Medicine, 2014, 14, s71-s77.	0.8	3
230	Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study. Cancer Prevention Research, 2014, 7, 211-217.	0.7	192
231	Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biology, 2014, 15, 431.	3.8	178
232	Genome-based approaches for the diagnosis of breast cancer: a review with perspective. Breast Cancer Management, 2014, 3, 173-193.	0.2	0
233	JNK Suppresses Tumor Formation via a Gene-Expression Program Mediated by ATF2. Cell Reports, 2014, 9, 1361-1374.	2.9	43
234	Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia. Leukemia, 2014, 28, 1844-1850.	3.3	42
235	The AURORA initiative for metastatic breast cancer. British Journal of Cancer, 2014, 111, 1881-1887.	2.9	77

#	ARTICLE	IF	CITATIONS
236	Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. <i>Modern Pathology</i> , 2014, 27, 740-750.	2.9	47
237	Processed pseudogenes acquired somatically during cancer development. <i>Nature Communications</i> , 2014, 5, 3644.	5.8	86
238	A framework for organizing cancer-related variations from existing databases, publications and NGS data using a High-performance Integrated Virtual Environment (HIVE). <i>Database: the Journal of Biological Databases and Curation</i> , 2014, 2014, bau022.	1.4	62
239	Is homologous recombination really an error-free process?. <i>Frontiers in Genetics</i> , 2014, 5, 175.	1.1	106
240	Whole-Exome Sequencing of Patients with Severe Disorders of Insulin Action. <i>Frontiers in Diabetes</i> , 2014, , 87-101.	0.4	0
241	Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine. <i>BioMed Research International</i> , 2014, 2014, 1-17.	0.9	11
242	Induction of Wnt-Inducible Signaling Protein-1 Correlates with Invasive Breast Cancer Oncogenesis and Reduced Type 1 Cell-Mediated Cytotoxic Immunity: A Retrospective Study. <i>PLoS Computational Biology</i> , 2014, 10, e1003409.	1.5	43
243	Subclonal variant calling with multiple samples and prior knowledge. <i>Bioinformatics</i> , 2014, 30, 1198-1204.	1.8	122
244	The relationship between delay period eye movements and visuospatial memory. <i>Journal of Vision</i> , 2014, 14, 8-8.	0.1	72
245	Systems consequences of amplicon formation in human breast cancer. <i>Genome Research</i> , 2014, 24, 1559-1571.	2.4	32
246	Do epigenetic drug treatments hold the key to killing cancer progenitor cells?. <i>Epigenomics</i> , 2014, 6, 161-165.	1.0	28
247	Metronomic Chemotherapy. , 2014, , .		3
248	Exome sequencing reveals frequent inactivating mutations in <i>ARID1A</i> , <i>ARID1B</i> , <i>ARID2</i> and <i>ARID4A</i> in microsatellite unstable colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 611-623.	2.3	107
249	The <i>ARID1B</i> phenotype: What we have learned so far. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 276-289.	0.7	77
250	Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers. <i>Cell</i> , 2014, 159, 1461-1475.	13.5	77
251	Mutations in exon 2 of <i>TBX3</i> are rare in common human tumors. <i>Apmis</i> , 2014, 122, 161-163.	0.9	0
252	Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2014, 6, 93-106.	6.6	18
253	Erroneous identification of APOBEC3-edited chromosomal DNA in cancer genomics. <i>British Journal of Cancer</i> , 2014, 110, 2615-2622.	2.9	10

#	ARTICLE	IF	CITATIONS
254	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. British Journal of Surgery, 2014, 101, 925-938.	0.1	34
255	<i>GATA3</i> mutations define a unique subtype of luminal-like breast cancer with improved survival. Cancer, 2014, 120, 1329-1337.	2.0	60
256	Splicing factor mutations and cancer. Wiley Interdisciplinary Reviews RNA, 2014, 5, 445-459.	3.2	126
257	Ultrasonic strain effects on Bi2223 cuprate superconductors. Japanese Journal of Applied Physics, 2014, 53, 07KC05.	0.8	1
258	DUST IN ACTIVE GALACTIC NUCLEI: ANOMALOUS SILICATE TO OPTICAL EXTINCTION RATIOS?. Astrophysical Journal Letters, 2014, 792, L9.	3.0	20
259	Evolving concepts of tumor heterogeneity. Cell and Bioscience, 2014, 4, 69.	2.1	59
260	Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. Breast Cancer Research, 2014, 16, R46.	2.2	40
261	A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Research, 2014, 42, 6106-6127.	6.5	72
262	New concepts in breast cancer genomics and genetics. Breast Cancer Research, 2014, 16, 460.	2.2	28
263	DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression. Clinical Cancer Research, 2014, 20, 1489-1501.	3.2	10
264	Chromatin-regulating proteins as targets for cancer therapy. Journal of Radiation Research, 2014, 55, 613-628.	0.8	28
265	Sequencing efforts help to refine the molecular classification of breast cancer. Current Opinion in Obstetrics and Gynecology, 2014, 26, 18-20.	0.9	0
266	Practicing Pathology in the Era of Big Data and Personalized Medicine. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 1-9.	0.6	47
267	NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database: the Journal of Biological Databases and Curation, 2014, 2014, bau015.	1.4	50
268	The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data. Nucleic Acids Research, 2014, 42, e172-e172.	6.5	33
269	Favorable Prognostic Impact in Loss of <i>TP53</i> and <i>PIK3CA</i> Mutations after Neoadjuvant Chemotherapy in Breast Cancer. Cancer Research, 2014, 74, 3399-3407.	0.4	37
270	Theranostic and Molecular Classification of Breast Cancer. Archives of Pathology and Laboratory Medicine, 2014, 138, 44-56.	1.2	40
271	HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients. Japanese Journal of Clinical Oncology, 2014, 44, 619-623.	0.6	11

#	ARTICLE	IF	CITATIONS
272	Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nursesâ€™ Health Study. Breast Cancer Research and Treatment, 2014, 147, 639-651.	1.1	45
273	Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations. Journal of Hepatology, 2014, 61, 1178-1183.	1.8	48
274	Omics Approaches in Breast Cancer. , 2014, , .		10
275	Breast Cancer Genomics. , 2014, , 53-103.		0
276	Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics. Frontiers in Oncology, 2014, 4, 78.	1.3	71
277	Whole exome sequencing for cancer – is there evidence of clinical utility?. Advances in Genomics and Genetics, 2014, , 115.	0.8	2
278	Inferring copy number and genotype in tumour exome data. BMC Genomics, 2014, 15, 732.	1.2	102
279	PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Research, 2014, 16, 201.	2.2	94
280	Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study. Journal of Clinical Oncology, 2014, 32, 2951-2958.	0.8	101
281	Clinical value of isoform-specific detection and targeting of AKT1, AKT2 and AKT3 in breast cancer. Breast Cancer Management, 2014, 3, 409-421.	0.2	3
282	Cross-Species Analysis of Mouse and Human Cancer Genomes. Cold Spring Harbor Protocols, 2014, 2014, pdb.top078824.	0.2	7
283	Individualizing breast cancer treatmentâ€”The dawn of personalized medicine. Experimental Cell Research, 2014, 320, 1-11.	1.2	26
284	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. Cell Reports, 2014, 6, 514-527.	2.9	239
285	Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genetics, 2014, 207, 365-372.	0.2	119
286	The Potential of Targeting Splicing for Cancer Therapy. Cancer Drug Discovery and Development, 2014, , 313-336.	0.2	1
288	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Research and Treatment, 2014, 143, 385-392.	1.1	54
289	Low Prognostic Implication of Fibroblast Growth Factor Family Activation in Triple-negative Breast Cancer Subsets. Annals of Surgical Oncology, 2014, 21, 1561-1568.	0.7	55
290	Emergence of Constitutively Active Estrogen Receptor-Î± Mutations in Pretreated Advanced Estrogen Receptorâ€”Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767.	3.2	529

#	ARTICLE	IF	CITATIONS
291	Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 52-60.	1.5	393
292	Evolution of the Cancer Stem Cell Model. <i>Cell Stem Cell</i> , 2014, 14, 275-291.	5.2	1,825
293	NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2630-2638.	0.3	287
294	Estrogen receptor (ER) \pm mutations in breast cancer: hidden in plain sight. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 11-19.	1.1	67
295	Molecular tests as prognostic factors in breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 283-291.	1.4	35
296	Nuclear Mechanics in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014, 773, 435-470.	0.8	125
297	Epistatic interactions and drug response. <i>Journal of Pathology</i> , 2014, 232, 255-263.	2.1	24
298	Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. <i>Oncogene</i> , 2014, 33, 4767-4777.	2.6	76
299	Principles and methods of integrative genomic analyses in cancer. <i>Nature Reviews Cancer</i> , 2014, 14, 299-313.	12.8	337
300	The challenge of intratumour heterogeneity in precision medicine. <i>Journal of Internal Medicine</i> , 2014, 276, 41-51.	2.7	66
301	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene-Environment Interactions. <i>Genetic Epidemiology</i> , 2014, 38, 84-93.	0.6	28
302	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. <i>Journal of Pathology</i> , 2014, 232, 274-282.	2.1	48
303	Enriched variations in TEK4 and breast cancer resistance to paclitaxel. <i>Nature Communications</i> , 2014, 5, 3802.	5.8	34
304	Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 88-100.	1.4	34
305	Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes. <i>Human Molecular Genetics</i> , 2014, 23, 5378-5393.	1.4	31
306	DNA Sequencing of Cancer: What Have We Learned?. <i>Annual Review of Medicine</i> , 2014, 65, 63-79.	5.0	41
307	The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. <i>Advanced Drug Delivery Reviews</i> , 2014, 69-70, 42-51.	6.6	273
308	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	5.8	741

#	ARTICLE	IF	CITATIONS
309	Transmissible Dog Cancer Genome Reveals the Origin and History of an Ancient Cell Lineage. <i>Science</i> , 2014, 343, 437-440.	6.0	144
310	Breast Cancer Genomics. , 2014, , 213-232.		4
311	The evolution of the unstable cancer genome. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 61-67.	1.5	62
312	Inactivating CUX1 mutations promote tumorigenesis. <i>Nature Genetics</i> , 2014, 46, 33-38.	9.4	111
313	A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. <i>Oncologist</i> , 2014, 19, 453-458.	1.9	53
314	Molecular Homology and Difference between Spontaneous Canine Mammary Cancer and Human Breast Cancer. <i>Cancer Research</i> , 2014, 74, 5045-5056.	0.4	110
315	Multicenter Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) Identifies Proteomic Differences in Breast-Cancer-Associated Stroma. <i>Journal of Proteome Research</i> , 2014, 13, 4730-4738.	1.8	72
316	ChromoHub V2: cancer genomics. <i>Bioinformatics</i> , 2014, 30, 590-592.	1.8	11
317	Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. <i>Breast Cancer Research</i> , 2014, 16, 205.	2.2	56
318	CARM1 and BAF155: an example of how chromatin remodeling factors can be relocalized and contribute to cancer. <i>Breast Cancer Research</i> , 2014, 16, 307.	2.2	1
319	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. <i>Genome Medicine</i> , 2014, 6, 5.	3.6	186
320	Biology of breast cancer in young women. <i>Breast Cancer Research</i> , 2014, 16, 427.	2.2	296
321	The kinome associated with estrogen receptor-positive status in human breast cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, R357-R370.	1.6	5
322	SWI/SNF chromatin remodeling complexes and cancer. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2014, 166, 350-366.	0.7	155
323	Integrative Identification of Epstein-Barr Virus-Associated Mutations and Epigenetic Alterations in Gastric Cancer. <i>Gastroenterology</i> , 2014, 147, 1350-1362.e4.	0.6	90
324	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. <i>Annals of Oncology</i> , 2014, 25, 1959-1965.	0.6	206
325	A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. <i>Nature Communications</i> , 2014, 5, 5129.	5.8	111
326	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. <i>Nature Communications</i> , 2014, 5, 5006.	5.8	149

#	ARTICLE	IF	CITATIONS
327	The SMRT Coregulator Enhances Growth of Estrogen Receptor-Positive Breast Cancer Cells by Promotion of Cell Cycle Progression and Inhibition of Apoptosis. <i>Endocrinology</i> , 2014, 155, 3251-3261.	1.4	16
328	Translating Genomics for Precision Cancer Medicine. <i>Annual Review of Genomics and Human Genetics</i> , 2014, 15, 395-415.	2.5	63
329	Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. <i>Nature Genetics</i> , 2014, 46, 877-880.	9.4	172
330	Reconstructing the coding and non-coding RNA regulatory networks of miRNAs and mRNAs in breast cancer. <i>Gene</i> , 2014, 548, 6-13.	1.0	18
331	Analysis of Chemotherapeutic Response in Ovarian Cancers Using Publicly Available High-Throughput Data. <i>Cancer Research</i> , 2014, 74, 3902-3912.	0.4	34
332	Focal chromosomal copy number aberrations in cancer—Needles in a genome haystack. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 2698-2704.	1.9	55
333	Lentiviral Vector-based Insertional Mutagenesis Identifies Genes Involved in the Resistance to Targeted Anticancer Therapies. <i>Molecular Therapy</i> , 2014, 22, 2056-2068.	3.7	16
334	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. <i>Science</i> , 2014, 346, 256-259.	6.0	834
335	Is target validation all we need?. <i>Current Opinion in Pharmacology</i> , 2014, 17, 81-86.	1.7	5
336	Family-specific, novel, deleterious germline variants provide a rich resource to identify genetic predispositions for BRCAx familial breast cancer. <i>BMC Cancer</i> , 2014, 14, 470.	1.1	16
337	The molecular landscape of the normal human breast — defining normal. <i>Breast Cancer Research</i> , 2014, 16, 102.	2.2	0
338	Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. <i>BMC Medicine</i> , 2014, 12, 140.	2.3	36
339	Cancer: Evolution Within a Lifetime. <i>Annual Review of Genetics</i> , 2014, 48, 215-236.	3.2	196
340	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. <i>Science</i> , 2014, 346, 251-256.	6.0	962
341	Construction of breast cancer gene regulatory networks and drug target optimization. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 749-755.	0.8	6
343	SWI/SNF Factors Required for Cellular Resistance to DNA Damage Include ARID1A and ARID1B and Show Interdependent Protein Stability. <i>Cancer Research</i> , 2014, 74, 2465-2475.	0.4	140
344	JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI. <i>Breast Cancer Research</i> , 2014, 16, R56.	2.2	46
345	STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. <i>Genome Medicine</i> , 2014, 6, 9.	3.6	23

#	ARTICLE	IF	CITATIONS
346	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014, 21, 545-554.	1.6	58
347	Toxicogenomics and Cancer Susceptibility: Advances with Next-Generation Sequencing. <i>Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews</i> , 2014, 32, 121-158.	2.9	32
348	Radiopharmaceutical therapy in the era of precision medicine. <i>European Journal of Cancer</i> , 2014, 50, 2360-2363.	1.3	16
349	Revisiting the role of MCL1 in tumorigenesis of solid cancer: gene expression correlates with antiproliferative phenotype in breast cancer cells and its functional regulatory variants are associated with reduced cancer susceptibility. <i>Tumor Biology</i> , 2014, 35, 8289-8299.	0.8	2
350	Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover. <i>BMC Cancer</i> , 2014, 14, 278.	1.1	47
351	Tackling the cancer stem cells “what challenges do they pose?”. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 497-512.	21.5	831
352	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1089-1095.	3.4	30
353	Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 4314-4325.	3.2	48
354	The 41st David A. Karnofsky Memorial Award Lecture: Academic Research Worldwide “Quo Vadis?”. <i>Journal of Clinical Oncology</i> , 2014, 32, 347-354.	0.8	35
355	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). <i>Lancet Oncology</i> , The, 2014, 15, 267-274.	5.1	351
356	A community effort to assess and improve drug sensitivity prediction algorithms. <i>Nature Biotechnology</i> , 2014, 32, 1202-1212.	9.4	653
357	Accumulation of Somatic Mutations in TP53 in Gastric Epithelium With <i>Helicobacter pylori</i> Infection. <i>Gastroenterology</i> , 2014, 147, 407-417.e3.	0.6	121
358	SAFIR01: steps towards precision treatment in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, 242-243.	5.1	8
359	The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming. <i>Cell Reports</i> , 2014, 6, 141-154.	2.9	48
360	Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 633-641.	1.6	53
361	Collection, integration and analysis of cancer genomic profiles: from data to insight. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 92-98.	1.5	22
362	Personalized medicine: Present and future of breast cancer management. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 223-233.	2.0	49
363	KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer. <i>Neoplasia</i> , 2014, 16, 247-256.e2.	2.3	69

#	ARTICLE	IF	CITATIONS
365	Steering tumor progression through the transcriptional response to growth factors and stroma. <i>FEBS Letters</i> , 2014, 588, 2407-2414.	1.3	7
366	Molecular classification of breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 1-14.	1.4	149
367	Reading between the lines; understanding drug response in the post genomic era. <i>Molecular Oncology</i> , 2014, 8, 1112-1119.	2.1	12
368	Epidemiology of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 409-422.	0.6	130
369	The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases. <i>Oncogene</i> , 2014, 33, 2681-2689.	2.6	64
371	Wnt5a Promotes Migration of Human Osteosarcoma Cells by Triggering a Phosphatidylinositol-3 Kinase/Akt Signals. , 2014, , 129-144.		0
372	<scp>eEF</scp>2Kâ€”a new target in breast cancers with combined inactivation of p53 and PTEN. <i>EMBO Molecular Medicine</i> , 2014, 6, 1512-1514.	3.3	7
373	A simple approach for classifying new mutations as somatic or germinal in DNA samples lacking paired tissue. <i>BioTechniques</i> , 2014, 56, 327-9.	0.8	1
376	SeqAssist: a novel toolkit for preliminary analysis of next-generation sequencing data. <i>BMC Bioinformatics</i> , 2014, 15, S10.	1.2	7
377	Associating spatial diversity features of radiologically defined tumor habitats with epidermal growth factor receptor driver status and 12-month survival in glioblastoma: methods and preliminary investigation. <i>Journal of Medical Imaging</i> , 2015, 2, 041006.	0.8	32
378	Identification of several potential chromatin binding sites of HOXB7 and its downstream target genes in breast cancer. <i>International Journal of Cancer</i> , 2015, 137, 2374-2383.	2.3	28
379	Breast cancer heterogeneity: parallel evolution or conscious uncoupling?. <i>Journal of Pathology</i> , 2015, 237, 1-3.	2.1	2
380	Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. <i>Cancer Medicine</i> , 2015, 4, 1289-1293.	1.3	7
381	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. <i>Blood</i> , 2015, 125, 499-503.	0.6	115
382	Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an <i>ERBB2</i>S310F Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1066-1070.	2.3	31
383	Targeting Breast Cancer Metastasis. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9s1, BCBCR.S25460.	0.6	145
384	Computational methods and resources for the interpretation of genomic variants in cancer. <i>BMC Genomics</i> , 2015, 16, S7.	1.2	18
385	A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. <i>Breast Cancer Research</i> , 2015, 17, 4.	2.2	24

#	ARTICLE	IF	CITATIONS
386	Chromatin interaction analysis reveals changes in small chromosome and telomere clustering between epithelial and breast cancer cells. <i>Genome Biology</i> , 2015, 16, 214.	3.8	206
387	The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. <i>Clinical Epigenetics</i> , 2015, 7, 57.	1.8	75
388	Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients. <i>Human Mutation</i> , 2015, 36, 1088-1099.	1.1	11
389	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. <i>Journal of Pathology</i> , 2015, 237, 363-378.	2.1	98
390	Can Peto's paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review. <i>BMC Cancer</i> , 2015, 15, 792.	1.1	17
391	Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. <i>BMC Systems Biology</i> , 2015, 9, 62.	3.0	40
392	TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. <i>Genome Medicine</i> , 2015, 7, 118.	3.6	78
393	PALB2 mutations in breast cancer patients from a multi-ethnic region in northwest China. <i>European Journal of Medical Research</i> , 2015, 20, 85.	0.9	11
394	The Significance and Therapeutic Potential of GATA3 Expression and Mutation in Breast Cancer: A Systematic Review. <i>Medicinal Research Reviews</i> , 2015, 35, 1300-1315.	5.0	16
395	GATA3 in Breast Cancer: Tumor Suppressor or Oncogene?. <i>Gene Expression</i> , 2015, 16, 163-168.	0.5	90
396	Detection of novel germline mutations for breast cancer in non-BRCA1/2 families. <i>FEBS Journal</i> , 2015, 282, 3424-3437.	2.2	50
397	Clinicopathological significance of ARID1B in breast invasive ductal carcinoma. <i>Histopathology</i> , 2015, 67, 709-718.	1.6	15
398	Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival. <i>Journal of Pathology</i> , 2015, 237, 152-165.	2.1	73
399	Precision Medicine for Metastatic Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e2-e7.	1.8	14
400	The recent progress of neoadjuvant chemotherapy in triple negative breast cancer: A short review. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	0
401	Evidence and potential clinical significance of changes in gene network interactions in ovarian cancer. <i>Journal of Biomedical Engineering and Informatics</i> , 2015, 2, 1.	0.2	2
402	Personalized Medicine in Cancer. <i>Journal of Bangladesh College of Physicians & Surgeons</i> , 2015, 32, 153-163.	0.0	0
403	Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients. <i>Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research</i> , 2015, 09, .	0.1	22

#	ARTICLE	IF	CITATIONS
404	Managing Single-Stranded DNA during Replication Stress in Fission Yeast. <i>Biomolecules</i> , 2015, 5, 2123-2139.	1.8	25
405	Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. <i>International Journal of Molecular Sciences</i> , 2015, 16, 19447-19457.	1.8	3
406	Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression. <i>Frontiers in Oncology</i> , 2015, 5, 244.	1.3	18
407	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. <i>Oncotarget</i> , 2015, 6, 32317-32338.	0.8	35
408	Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. <i>PLoS ONE</i> , 2015, 10, e0126762.	1.1	18
409	An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. <i>PLoS Computational Biology</i> , 2015, 11, e1004350.	1.5	25
410	Identification of High-Impact cis-Regulatory Mutations Using Transcription Factor Specific Random Forest Models. <i>PLoS Computational Biology</i> , 2015, 11, e1004590.	1.5	21
411	Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0144528.	1.1	6
412	Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis. <i>Revista Da Associação Médica Brasileira</i> , 2015, 61, 474-483.	0.3	18
413	Prognostic and predictive values of long non-coding RNA <i>LINC00472</i> in breast cancer. <i>Oncotarget</i> , 2015, 6, 8579-8592.	0.8	79
414	Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. <i>Oncotarget</i> , 2015, 6, 22985-22995.	0.8	16
415	Cyr61 as mediator of Src signaling in triple negative breast cancer cells. <i>Oncotarget</i> , 2015, 6, 13520-13538.	0.8	24
416	Genomic profiling of breast cancers. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 34-39.	0.9	19
417	Serial monitoring of circulating tumor <i>DNA</i> in patients with primary breast cancer for detection of occult metastatic disease. <i>EMBO Molecular Medicine</i> , 2015, 7, 1034-1047.	3.3	380
419	Genome-wide analysis of alternative transcripts in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 295-307.	1.1	26
420	Targeting the mammalian target of rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 433-442.	0.5	7
421	Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. <i>Clinical Cancer Research</i> , 2015, 21, 4165-4173.	3.2	78
422	The somatic autosomal mutation matrix in cancer genomes. <i>Human Genetics</i> , 2015, 134, 851-864.	1.8	16

#	ARTICLE	IF	CITATIONS
423	Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer. <i>Surgical Oncology</i> , 2015, 24, 100-109.	0.8	25
424	Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 2905-2910.	3.2	307
425	Progress of cancer genomics. <i>Thoracic Cancer</i> , 2015, 6, 557-560.	0.8	1
426	Personalized treatment of Zary syndrome by targeting a novel CTLA4:CD28 fusion. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 130-136.	0.6	73
427	Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer. <i>Cancer Science</i> , 2015, 106, 642-649.	1.7	17
428	Functional characterization of a CDKN1B mutation in a Sardinian kindred with multiple endocrine neoplasia type 4. <i>Endocrine Connections</i> , 2015, 4, 1-8.	0.8	44
429	Global transcription network incorporating distal regulator binding reveals selective cooperation of cancer drivers and risk genes. <i>Nucleic Acids Research</i> , 2015, 43, 5716-5729.	6.5	6
430	Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity. <i>Nucleic Acids Research</i> , 2015, 43, 7330-7348.	6.5	22
431	Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. <i>Breast Cancer Research</i> , 2015, 17, 134.	2.2	58
432	BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs. <i>Cancer Research</i> , 2015, 75, 1345-1355.	0.4	30
434	MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. <i>Breast Cancer Research</i> , 2015, 17, 83.	2.2	44
435	Molecular segmentation of luminal breast: Reality in 2015?. <i>Breast</i> , 2015, 24, S41-S43.	0.9	0
436	WIPI proteins: essential PtdIns3P effectors at the nascent autophagosome. <i>Journal of Cell Science</i> , 2015, 128, 207-17.	1.2	214
437	Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. <i>Molecular Oncology</i> , 2015, 9, 749-757.	2.1	146
438	Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. <i>Cancer Treatment Reviews</i> , 2015, 41, 129-135.	3.4	14
439	Runx3 at the interface of immunity, inflammation and cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 131-143.	3.3	69
440	Intratumoral heterogeneity and consequences for targeted therapies. <i>Bulletin Du Cancer</i> , 2015, 102, 17-23.	0.6	16
441	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 304-311.	0.8	521

#	ARTICLE	IF	CITATIONS
442	Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM+ AFP+ hepatocellular carcinoma. <i>Oncogene</i> , 2015, 34, 5095-5104.	2.6	57
443	Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 823-834.	1.5	3
444	CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. <i>Cancer Research</i> , 2015, 75, 1516-1526.	0.4	79
445	MAPK Genes Interact with Diet and Lifestyle Factors to Alter Risk of Breast Cancer: The Breast Cancer Health Disparities Study. <i>Nutrition and Cancer</i> , 2015, 67, 292-304.	0.9	20
446	Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing. <i>Tumor Biology</i> , 2015, 36, 3309-3317.	0.8	21
447	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	2.6	76
448	Intrinsic cancer subtypes-next steps into personalized medicine. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 3-16.	2.1	24
449	The future of breast cancer systemic therapy: the next 10Âyears. <i>Journal of Molecular Medicine</i> , 2015, 93, 119-125.	1.7	19
450	Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 298-306.	1.9	14
451	The Molecular Biology of Breast Cancer. , 2015, , 523-530.e3.		0
452	Understanding and Using Information about Cancer Genomes. , 2015, , 357-368.e3.		0
453	Breast Cancer Genomics From Microarrays to Massively Parallel Sequencing: Paradigms and New Insights. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	80
454	<i>APOBEC3B</i> expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2841-2846.	3.3	118
455	Targeting the Tumor Stroma in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 71-79.	0.5	0
456	Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 516-525.	2.7	36
457	The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. <i>Genome Medicine</i> , 2015, 7, 20.	3.6	129
458	Pathway-driven discovery of epilepsy genes. <i>Nature Neuroscience</i> , 2015, 18, 344-350.	7.1	158
459	Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments. <i>Current Oncology Reports</i> , 2015, 17, 15.	1.8	29

#	ARTICLE	IF	CITATIONS
460	PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 299-307.	1.1	120
461	The landscape of precision cancer medicine clinical trials in the United States. <i>Cancer Treatment Reviews</i> , 2015, 41, 385-390.	3.4	57
462	Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. <i>Oncogene</i> , 2015, 34, 5427-5435.	2.6	71
463	Personalised medicine in veterinary oncology: One to cure just one. <i>Veterinary Journal</i> , 2015, 205, 128-135.	0.6	17
464	Role of the double-strand break repair pathway in the maintenance of genomic stability. <i>Molecular and Cellular Oncology</i> , 2015, 2, e968020.	0.3	21
465	A Molecular Portrait of High-Grade Ductal Carcinoma <i>In Situ</i> . <i>Cancer Research</i> , 2015, 75, 3980-3990.	0.4	122
466	Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4369-4382.	2.4	35
467	What to expect from high throughput genomics in metastatic breast cancers?. <i>Breast</i> , 2015, 24, S19-S22.	0.9	4
468	Clinical overview of metronomic chemotherapy in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 631-644.	12.5	109
469	Gene-Expression-Based Predictors for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3418-3432.	0.7	24
470	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 479-496.	2.7	101
471	NF- κ B-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT. <i>Cell Death and Disease</i> , 2015, 6, e1608-e1608.	2.7	48
472	Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. <i>Science Advances</i> , 2015, 1, e1500447.	4.7	627
473	Breast cancer risk and possible mechanisms of radiation-induced genomic instability in the Swedish hemangioma cohort after reanalyzed dosimetry. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2015, 775, 1-9.	0.4	33
474	Surgery in the era of the 'omics revolution. <i>British Journal of Surgery</i> , 2015, 102, e29-e40.	0.1	9
476	Shp2 signaling suppresses senescence in <i>PyMT</i> -induced mammary gland cancer in mice. <i>EMBO Journal</i> , 2015, 34, 1493-1508.	3.5	31
477	Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity. <i>Molecular Aspects of Medicine</i> , 2015, 45, 3-13.	2.7	13
478	Estrogen receptor mutations and functional consequences for breast cancer. <i>Trends in Endocrinology and Metabolism</i> , 2015, 26, 467-476.	3.1	63

#	ARTICLE	IF	CITATIONS
479	Cancer in the parasitic protozoans <i>Trypanosoma brucei</i> and <i>Toxoplasma gondii</i> . Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8835-8842.	3.3	42
480	Precision medicine for metastatic breast cancer—limitations and solutions. Nature Reviews Clinical Oncology, 2015, 12, 693-704.	12.5	272
481	Identification of Constrained Cancer Driver Genes Based on Mutation Timing. PLoS Computational Biology, 2015, 11, e1004027.	1.5	22
482	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nature Medicine, 2015, 21, 751-759.	15.2	711
483	The cancer COMPASS: navigating the functions of MLL complexes in cancer. Cancer Genetics, 2015, 208, 178-191.	0.2	122
484	Protein Domain-Level Landscape of Cancer-Type-Specific Somatic Mutations. PLoS Computational Biology, 2015, 11, e1004147.	1.5	59
485	Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine. Expert Review of Proteomics, 2015, 12, 317-328.	1.3	48
486	Environmental and DNA repair risk factors for breast cancer in South China. International Journal of Hygiene and Environmental Health, 2015, 218, 313-318.	2.1	19
488	Cell signaling events differentiate ER-negative subtypes from ER-positive breast cancer. Medical Oncology, 2015, 32, 142.	1.2	7
489	Clinical management of breast cancer heterogeneity. Nature Reviews Clinical Oncology, 2015, 12, 381-394.	12.5	400
490	Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. Tumor Biology, 2015, 36, 1835-1848.	0.8	21
491	A mutation screening of oncogenes, tumor suppressor gene TP53 and nuclear encoded mitochondrial complex I genes in oncocytic thyroid tumors. BMC Cancer, 2015, 15, 157.	1.1	34
492	Molecular mechanism and clinical impact of APOBEC3B-catalyzed mutagenesis in breast cancer. Breast Cancer Research, 2015, 17, 8.	2.2	82
493	TET proteins and the control of cytosine demethylation in cancer. Genome Medicine, 2015, 7, 9.	3.6	176
494	Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science Signaling, 2015, 8, ra7.	1.6	53
495	EPMA position paper in cancer: current overview and future perspectives. EPMA Journal, 2015, 6, 9.	3.3	86
496	Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. DMM Disease Models and Mechanisms, 2015, 8, 237-51.	1.2	154
497	Whole-exome DNA sequence analysis of <i>Brca2</i> - and <i>Trp53</i> -deficient mouse mammary gland tumours. Journal of Pathology, 2015, 236, 186-200.	2.1	14

#	ARTICLE	IF	CITATIONS
498	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
499	Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications. Cancer Research, 2015, 75, 2243-2253.	0.4	62
500	Epigenetic Silencing of miR-490-3p Reactivates the Chromatin Remodeler SMARCD1 to Promote <i>Helicobacter pylori</i> -Induced Gastric Carcinogenesis. Cancer Research, 2015, 75, 754-765.	0.4	115
501	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics, 2015, 47, 367-372.	9.4	380
502	Somatic <i>POLE</i> mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology, 2015, 17, 1356-1364.	0.6	94
503	Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer. Genome Research, 2015, 25, 1521-1535.	2.4	25
504	Genomic landscapes of breast fibroepithelial tumors. Nature Genetics, 2015, 47, 1341-1345.	9.4	167
505	The RYK Receptor Family. , 2015, , 685-741.		6
506	The organochlorine pesticides residues in the invasive ductal breast cancer patients. Environmental Toxicology and Pharmacology, 2015, 40, 698-703.	2.0	13
507	Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology. Translational Oncology, 2015, 8, 407-416.	1.7	43
508	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 2015, 36, 822-846.	4.0	242
509	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. Breast Cancer Research and Treatment, 2015, 154, 287-297.	1.1	26
510	The unpredictable consequences of CDKN1B/p27Kip1 mutations in cancer. Cell Cycle, 2015, 14, 2865-2866.	1.3	0
511	A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients. Genome Medicine, 2015, 7, 104.	3.6	65
512	Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Medicine, 2015, 13, 137.	2.3	59
513	Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. Journal of Cellular Biochemistry, 2015, 116, 2824-2839.	1.2	19
514	Classical pathology and mutational load of breast cancer – integration of two worlds. Journal of Pathology: Clinical Research, 2015, 1, 225-238.	1.3	91
515	Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. Journal of Molecular Diagnostics, 2015, 17, 487-495.	1.2	53

#	ARTICLE	IF	CITATIONS
516	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in SÅ©zary syndrome. <i>Nature Communications</i> , 2015, 6, 8470.	5.8	177
517	Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation. <i>Genome Biology</i> , 2015, 16, 193.	3.8	19
518	Hormone-Sensing Mammary Epithelial Progenitors: Emerging Identity and Hormonal Regulation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2015, 20, 75-91.	1.0	12
519	Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals. <i>Cell Research</i> , 2015, 25, 1205-1218.	5.7	41
520	A seven-gene CpG-island methylation panel predicts breast cancer progression. <i>BMC Cancer</i> , 2015, 15, 417.	1.1	30
521	The mammary stem cell hierarchy: a looking glass into heterogeneous breast cancer landscapes. <i>Endocrine-Related Cancer</i> , 2015, 22, T161-T176.	1.6	45
522	Cancer Genetics and Implications for Clinical Management. <i>Surgical Clinics of North America</i> , 2015, 95, 919-934.	0.5	6
523	LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4894-900.	3.3	127
524	Myoepithelial Cell Differentiation Markers in Ductal Carcinoma in Situ Progression. <i>American Journal of Pathology</i> , 2015, 185, 3076-3089.	1.9	60
525	Durability of Kinase-Directed Therapies—A Network Perspective on Response and Resistance. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1975-1984.	1.9	22
526	Chromatin-Remodeling-Factor ARID1B Represses Wnt/ β 2-Catenin Signaling. <i>American Journal of Human Genetics</i> , 2015, 97, 445-456.	2.6	67
527	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1680-1691.	1.1	24
528	Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. <i>Translational Research</i> , 2015, 166, 540-553.e2.	2.2	55
529	Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells. <i>Nature</i> , 2015, 528, 267-271.	13.7	101
530	Personalized medicine in cancer: where are we today?. <i>Future Oncology</i> , 2015, 11, 2795-2798.	1.1	10
531	Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. <i>Molecular Cell</i> , 2015, 60, 537-546.	4.5	232
532	Considerations for Comprehensive Assessment of Genetic Predisposition in Familial Breast Cancer. <i>Breast Journal</i> , 2015, 21, 67-75.	0.4	14
533	Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer. <i>Scientific Reports</i> , 2014, 4, 7063.	1.6	41

#	ARTICLE	IF	CITATIONS
534	Pathway-level disease data mining through hyper-box principles. Mathematical Biosciences, 2015, 260, 25-34.	0.9	5
535	KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia, 2015, 29, 1177-1185.	3.3	156
536	APOBEC3A catabolism of electroporated plasmid DNA in mouse muscle. Gene Therapy, 2015, 22, 96-103.	2.3	5
537	<i>sf3b1</i> mutations constitute a novel therapeutic target in breast cancer. Journal of Pathology, 2015, 235, 571-580.	2.1	167
538	The impact of SF3B1 mutations in CLL on the DNA-damage response. Leukemia, 2015, 29, 1133-1142.	3.3	74
539	Is reduction of tumor burden sufficient for the 21st century?. Cancer Letters, 2015, 356, 149-155.	3.2	1
540	Driver and Passenger Mutations in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 25-50.	9.6	291
541	A DNA methylation-based definition of biologically distinct breast cancer subtypes. Molecular Oncology, 2015, 9, 555-568.	2.1	156
542	NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation. Oncogene, 2015, 34, 3780-3790.	2.6	40
543	Breast cancer classification: linking molecular mechanisms to disease prognosis. Briefings in Bioinformatics, 2015, 16, 461-474.	3.2	55
544	Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene, 2015, 34, 3617-3626.	2.6	211
545	Genomic Applications in Pathology. , 2015, , .		1
546	Signaling network analysis of genomic alterations predicts breast cancer drug targets. , 0, , 269-280.		0
547	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget, 2016, 7, 32731-32753.	0.8	30
548	Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget, 2016, 7, 26107-26119.	0.8	136
549	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. Cancer Research and Treatment, 2016, 48, 1338-1350.	1.3	56
550	Mutations of Chromatin Structure Regulating Genes in Human Malignancies. Current Protein and Peptide Science, 2016, 17, 411-437.	0.7	25
551	Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells. Oncotarget, 2016, 7, 23961-23974.	0.8	45

#	ARTICLE	IF	CITATIONS
552	Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors. <i>Cancers</i> , 2016, 8, 99.	1.7	4
553	Evaluation and Comparison of the In Vitro Cytotoxic Activity of <i>Withania somnifera</i> Methanolic and Ethanolic Extracts against MDA-MB-231 and Vero Cell Lines. <i>Scientia Pharmaceutica</i> , 2016, 84, 41-59.	0.7	23
554	Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b. <i>Frontiers in Genetics</i> , 2016, 7, 143.	1.1	20
555	A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 759.	1.8	38
556	Cancer Cell Fusion: Mechanisms Slowly Unravel. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1587.	1.8	41
557	p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. <i>BMC Cancer</i> , 2016, 16, 649.	1.1	25
558	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016, 11, e0163138.	1.1	8
559	Identifying Network Perturbation in Cancer. <i>PLoS Computational Biology</i> , 2016, 12, e1004888.	1.5	35
560	AKT in cancer: new molecular insights and advances in drug development. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 943-956.	1.1	209
561	Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus. <i>Cancer Research</i> , 2016, 76, 1916-1925.	0.4	7
562	The Hallmarks of Cancer from a Redox Perspective. <i>Antioxidants and Redox Signaling</i> , 2016, 25, 300-325.	2.5	82
563	The Expression of Cohesin Subunit SA2 Predicts Breast Cancer Survival. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 615-621.	0.6	11
564	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	1.1	16
565	Ordered genome change of plant and animal body cells revealed by the genome profiling method. <i>FEBS Letters</i> , 2016, 590, 2119-2126.	1.3	1
566	A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 8-17.	2.3	21
567	Systems Pharmacology and Pharmacodynamics. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , .	0.2	9
568	The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 575-588.	2.7	237
569	Cancer genes discovery based on integtating transcriptomic data and the impact of gene length. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
570	AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer, 2016, 16, 622.	1.1	65
571	Understanding of "Networks"™ In Vitro and/or In Vivo. , 2016, , 141-152.		0
572	Evolution of cellular morpho-phenotypes in cancer metastasis. Scientific Reports, 2016, 5, 18437.	1.6	81
573	iCAGES: integrated CANcer GENome Score for comprehensively prioritizing driver genes in personal cancer genomes. Genome Medicine, 2016, 8, 135.	3.6	45
574	Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews, 2016, 35, 547-573.	2.7	189
575	Biomarkers in the Clinic. , 2016, , 415-426.		0
576	Early dissemination seeds metastasis in breast cancer. Nature, 2016, 540, 552-558.	13.7	550
577	The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer. BMC Cancer, 2016, 16, 671.	1.1	23
578	Using Systems Pharmacology to Advance Oncology Drug Development. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 421-463.	0.2	1
579	SNooPer: a machine learning-based method for somatic variant identification from low-pass next-generation sequencing. BMC Genomics, 2016, 17, 912.	1.2	50
580	"Omics Approaches in Breast Cancer Research and Clinical Practice. Advances in Anatomic Pathology, 2016, 23, 356-367.	2.4	17
581	CDK Inhibitors in Normal and Malignant Cells. , 2016, , 437-446.		1
582	Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer. Cancer Cell International, 2016, 16, 23.	1.8	11
583	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature Reviews Clinical Oncology, 2016, 13, 674-690.	12.5	1,938
584	Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Drug Resistance Updates, 2016, 27, 14-29.	6.5	511
585	Epigenetic Advancements in Cancer. , 2016, , .		1
586	Cohesin mutations in human cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 1-11.	3.3	101
587	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Research, 2016, 76, 1942-1953.	0.4	77

#	ARTICLE	IF	CITATIONS
588	Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population. BMC Cancer, 2016, 16, 165.	1.1	20
589	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30, 1672-1681.	3.3	99
590	The non-canonical functions of p27Kip1 in normal and tumor biology. Cell Cycle, 2016, 15, 1189-1201.	1.3	68
591	Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nature Cell Biology, 2016, 18, 572-578.	4.6	197
592	Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 2016, 533, 420-424.	13.7	3,662
593	Sparse group factor analysis for biclustering of multiple data sources. Bioinformatics, 2016, 32, 2457-2463.	1.8	28
594	The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. Expert Review of Molecular Diagnostics, 2016, 16, 751-755.	1.5	21
595	Re-Evaluating Clonal Dominance in Cancer Evolution. Trends in Cancer, 2016, 2, 263-276.	3.8	39
596	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	13.7	1,760
597	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews, 2016, 96, 805-829.	13.1	49
598	Emerging Biomarkers of the Future: Changing Clinical Practice for 2020. Current Breast Cancer Reports, 2016, 8, 60-72.	0.5	1
599	Tumor suppressive actions of the nuclear receptor corepressor 1. Pharmacological Research, 2016, 108, 75-79.	3.1	8
600	Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth. Cell Reports, 2016, 15, 2679-2691.	2.9	65
601	Current Status of Clinical Genomics in Patients with Metastatic Breast Cancer. Breast Diseases, 2016, 27, 182-186.	0.0	0
602	Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas. Cell Reports, 2016, 17, 249-260.	2.9	21
603	The genomic landscape of breast cancer and its interaction with host immunity. Breast, 2016, 29, 241-250.	0.9	194
604	Big Data Analytics. , 2016, , .		9
605	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist, 2016, 21, 1063-1078.	1.9	41

#	ARTICLE	IF	CITATIONS
606	Protein Tyrosine Phosphatases in Cancer. , 2016, , .		4
607	Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026179.	2.9	176
608	Role of PTPN11 (SHP2) in Cancer. , 2016, , 115-143.		11
609	Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. Molecular Genetics & Genomic Medicine, 2016, 4, 262-272.	0.6	11
610	An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer. British Journal of Cancer, 2016, 115, 752-760.	2.9	16
611	Molecular Concordance Between Primary Breast Cancer and Matched Metastases. Breast Journal, 2016, 22, 420-430.	0.4	44
612	Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer. Cancer Science, 2016, 107, 491-498.	1.7	40
613	Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer. Recent Results in Cancer Research, 2016, 207, 39-72.	1.8	143
614	Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer. BMC Genomics, 2016, 17, 525.	1.2	172
616	Novel Approaches to Apoptosis-Inducing Therapies. Advances in Experimental Medicine and Biology, 2016, 930, 173-204.	0.8	17
617	Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. Journal of Pathology, 2016, 240, 315-328.	2.1	35
618	Data on affected cancer-related genes in pediatric t(12;21)-positive acute lymphoblastic leukemia patients harboring unbalanced der(6)t(X;6) translocations. Data in Brief, 2016, 8, 894-903.	0.5	0
619	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Therapeutic Advances in Medical Oncology, 2016, 8, 360-374.	1.4	37
620	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population. Npj Breast Cancer, 2016, 2, 16022.	2.3	21
621	Mutational patterns in oncogenes and tumour suppressors. Biochemical Society Transactions, 2016, 44, 925-931.	1.6	16
622	Transposon mutagenesis identifies genes that cooperate with mutant Pten in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7749-E7758.	3.3	48
623	miR-520e regulates cell proliferation, apoptosis and migration in breast cancer. Oncology Letters, 2016, 12, 3543-3548.	0.8	16
624	One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer and Metastasis Reviews, 2016, 35, 601-629.	2.7	58

#	ARTICLE	IF	CITATIONS
625	A microscopic landscape of the invasive breast cancer genome. Scientific Reports, 2016, 6, 27545.	1.6	33
626	Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation. Nature Communications, 2016, 7, 13294.	5.8	34
627	A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nature Communications, 2016, 7, 12222.	5.8	113
628	Progress in the clinical detection of heterogeneity in breast cancer. Cancer Medicine, 2016, 5, 3475-3488.	1.3	50
629	Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop. Advances in Protein Chemistry and Structural Biology, 2016, 102, 147-179.	1.0	2
630	Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 141-150.	2.0	10
631	Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers. Cell Discovery, 2016, 2, 16025.	3.1	77
632	The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. BMC Genomics, 2016, 17, 442.	1.2	25
633	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature Communications, 2016, 7, 12910.	5.8	119
634	Glycosyltransferase Gene Expression Profiles Classify Cancer Types and Propose Prognostic Subtypes. Scientific Reports, 2016, 6, 26451.	1.6	63
635	Whole-exome sequencing identifies recurrent <i>AKT1</i> mutations in sclerosing hemangioma of lung. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10672-10677.	3.3	42
636	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 7, 11479.	5.8	1,221
637	COPS5 amplification and overexpression confers tamoxifen-resistance in ER \pm -positive breast cancer by degradation of NCoR. Nature Communications, 2016, 7, 12044.	5.8	56
638	Big Data and Cancer Research. , 2016, , 259-276.		1
639	The correlation between DNMT1 and ER \pm expression and the methylation status of ER \pm , and its clinical significance in breast cancer. Oncology Letters, 2016, 11, 1995-2000.	0.8	14
640	RNA splicing factors as oncoproteins and tumour suppressors. Nature Reviews Cancer, 2016, 16, 413-430.	12.8	549
641	Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management. Breast, 2016, 28, 136-144.	0.9	101
642	Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. Genes and Development, 2016, 30, 1470-1480.	2.7	113

#	ARTICLE	IF	CITATIONS
643	Les essais cliniques : leur apport dans le parcours de soins des patientes traitées pour un cancer du sein. <i>Oncologie</i> , 2016, 18, 103-108.	0.2	1
644	Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance. <i>Journal of Bone Oncology</i> , 2016, 5, 67-73.	1.0	50
645	Epigenetics of Breast Cancer: DNA Methylome and Global Histone Modifications. , 2016, , 207-228.		2
646	APOBEC3DE Antagonizes Hepatitis B Virus Restriction Factors APOBEC3F and APOBEC3G. <i>Journal of Molecular Biology</i> , 2016, 428, 3514-3528.	2.0	19
647	Immortalization of epithelial cells in oral carcinogenesis as revealed by genome-wide array comparative genomic hybridization: A meta-analysis. <i>Head and Neck</i> , 2016, 38, E783-97.	0.9	6
648	Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes. <i>JAMA Oncology</i> , 2016, 2, 1354.	3.4	426
649	Epigenomic regulation of oncogenesis by chromatin remodeling. <i>Oncogene</i> , 2016, 35, 4423-4436.	2.6	86
650	Cell-free circulating tumour DNA as a liquid biopsy in breast cancer. <i>Molecular Oncology</i> , 2016, 10, 464-474.	2.1	101
651	Curing Metastatic Breast Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 6-10.	2.5	60
652	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. <i>Cell</i> , 2016, 164, 293-309.	13.5	399
653	ARID1A gene mutation in ovarian and endometrial cancers (Review). <i>Oncology Reports</i> , 2016, 35, 607-613.	1.2	136
654	BRCAness revisited. <i>Nature Reviews Cancer</i> , 2016, 16, 110-120.	12.8	976
655	AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70.		49
656	A 2015 survey of established or potential epigenetic biomarkers for the accurate detection of human cancers. <i>Biomarkers</i> , 2016, 21, 387-403.	0.9	4
657	CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 692-700.	2.2	6
658	Mutation of cancer driver <i>MLL2</i> results in transcription stress and genome instability. <i>Genes and Development</i> , 2016, 30, 408-420.	2.7	112
659	Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships. <i>Molecular Oncology</i> , 2016, 10, 360-370.	2.1	41
660	Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas. <i>Cancer Genetics</i> , 2016, 209, 30-35.	0.2	26

#	ARTICLE	IF	CITATIONS
661	The three-dimensional cancer genome. <i>Current Opinion in Genetics and Development</i> , 2016, 36, 1-7.	1.5	72
662	Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. <i>Nature Reviews Genetics</i> , 2016, 17, 284-299.	7.7	679
663	Whole exome sequencing of rare aggressive breast cancer histologies. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 21-32.	1.1	38
664	Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptorâ€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1987-1994.	0.8	84
665	Microfluidics: Rapid Diagnosis for Breast Cancer. <i>Nano-Micro Letters</i> , 2016, 8, 204-220.	14.4	21
666	Catalog of genetic progression of human cancers: breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 49-62.	2.7	18
667	SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 638-643.	3.3	66
668	Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E328-37.	3.3	41
669	De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridgeâ€“Ropers syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 597-608.	1.4	56
671	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
672	Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. <i>Oncogene</i> , 2016, 35, 1743-1749.	2.6	13
673	Progress of Circulating Tumor Cells in Cancer Management. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 509-516.	0.8	3
674	Transcript expression and genetic variability analysis of caspases in breast carcinomas suggests CASP9 as the most interesting target. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 111-122.	1.4	0
675	Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patientsâ€™ survival. <i>Scientific Reports</i> , 2017, 7, 40177.	1.6	12
676	Probing the metabolic phenotype of breast cancer cells by multiple tracer stable isotope resolved metabolomics. <i>Metabolic Engineering</i> , 2017, 43, 125-136.	3.6	45
677	A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	119
678	Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer. <i>Clinical Chemistry</i> , 2017, 63, 532-541.	1.5	81
679	Inhibition of Ubc13-mediated Ubiquitination by GPS2 Regulates Multiple Stages of B Cell Development. <i>Journal of Biological Chemistry</i> , 2017, 292, 2754-2772.	1.6	30

#	ARTICLE	IF	CITATIONS
680	Marked for death: targeting epigenetic changes in cancer. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 241-263.	21.5	244
681	Genomic Analyses of Breast Cancer Progression Reveal Distinct Routes of Metastasis Emergence. <i>Scientific Reports</i> , 2017, 7, 43813.	1.6	24
682	B-Myb Induces APOBEC3B Expression Leading to Somatic Mutation in Multiple Cancers. <i>Scientific Reports</i> , 2017, 7, 44089.	1.6	26
683	Galangin potentiates human breast cancer to apoptosis induced by TRAIL through activating AMPK. <i>Biomedicine and Pharmacotherapy</i> , 2017, 89, 845-856.	2.5	38
684	Functional germline variants in driver genes of breast cancer. <i>Cancer Causes and Control</i> , 2017, 28, 259-271.	0.8	12
685	Micro-RNA detection based on fluorescence resonance energy transfer of DNA-carbon quantum dots probes. <i>Analytical Biochemistry</i> , 2017, 523, 32-38.	1.1	58
686	The importance of regulatory ubiquitination in cancer and metastasis. <i>Cell Cycle</i> , 2017, 16, 634-648.	1.3	134
687	Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2215-E2224.	3.3	34
688	Breast cancer in young women: an overview. <i>Updates in Surgery</i> , 2017, 69, 313-317.	0.9	442
689	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	9.4	112
690	AKT/PKB Signaling: Navigating the Network. <i>Cell</i> , 2017, 169, 381-405.	13.5	2,454
691	Breast cancers are rare diseases” and must be treated as such. <i>Npj Breast Cancer</i> , 2017, 3, 11.	2.3	11
692	Natural and chemotherapy-induced clonal evolution of tumors. <i>Biochemistry (Moscow)</i> , 2017, 82, 413-425.	0.7	30
693	<i>HER2</i> somatic mutations are associated with poor survival in HER2-negative breast cancers. <i>Cancer Science</i> , 2017, 108, 671-677.	1.7	53
694	Association Study Confirmed Three Breast Cancer-Specific Molecular Subtype-Associated Susceptibility Loci in Chinese Han Women. <i>Oncologist</i> , 2017, 22, 890-894.	1.9	14
695	Self-cytoplasmic DNA upregulates the mutator enzyme APOBEC3A leading to chromosomal DNA damage. <i>Nucleic Acids Research</i> , 2017, 45, gkx001.	6.5	23
696	Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer-Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 525-536.	1.2	64
697	Evaluation of a novel approach to circulating tumor cell isolation for cancer gene panel analysis in patients with breast cancer. <i>Oncology Letters</i> , 2017, 13, 3025-3031.	0.8	9

#	ARTICLE	IF	CITATIONS
698	Paratesticular desmoplastic small round cell tumors: A case report and review of the literature. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26631.	0.8	13
699	Somatic Tumor Mutations Detected by Targeted Next Generation Sequencing in Minute Amounts of Serum-Derived Cell-Free DNA. <i>Scientific Reports</i> , 2017, 7, 2136.	1.6	7
700	Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. <i>Nature Communications</i> , 2017, 8, 15936.	5.8	179
701	Physical Exercise Positively Influences Breast Cancer Evolution. <i>Clinical Breast Cancer</i> , 2017, 17, 408-417.	1.1	58
702	Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. <i>Modern Pathology</i> , 2017, 30, 1086-1099.	2.9	63
703	The Damaging Effect of Passenger Mutations on Cancer Progression. <i>Cancer Research</i> , 2017, 77, 4763-4772.	0.4	78
704	MicroRNA-548c-3p inhibits T98G glioma cell proliferation and migration by downregulating c-Myb. <i>Oncology Letters</i> , 2017, 13, 3866-3872.	0.8	22
705	Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2630-2639.	3.2	30
706	Mutational Signatures in Breast Cancer: The Problem at the DNA Level. <i>Clinical Cancer Research</i> , 2017, 23, 2617-2629.	3.2	102
707	Oncogenic Roles of the PI3K/AKT/mTOR Axis. <i>Current Topics in Microbiology and Immunology</i> , 2017, 407, 153-189.	0.7	242
708	Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures. <i>Trends in Genetics</i> , 2017, 33, 336-348.	2.9	56
709	Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination. <i>Journal of Hepatology</i> , 2017, 67, 186-191.	1.8	7
710	Computational approach for deriving cancer progression roadmaps from static sample data. <i>Nucleic Acids Research</i> , 2017, 45, gkx003.	6.5	13
711	Longitudinal analysis of treatment-induced genomic alterations in gliomas. <i>Genome Medicine</i> , 2017, 9, 12.	3.6	20
712	Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 587-594.	1.1	9
713	Runx3 in Immunity, Inflammation and Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 962, 369-393.	0.8	43
714	Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy. <i>Biotechnic and Histochemistry</i> , 2017, 92, 175-200.	0.7	10
715	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	13.7	229

#	ARTICLE	IF	CITATIONS
716	The genetic landscape of breast carcinomas with neuroendocrine differentiation. Journal of Pathology, 2017, 241, 405-419.	2.1	52
717	Metabotypes of breast cancer cell lines revealed by non-targeted metabolomics. Metabolic Engineering, 2017, 43, 173-186.	3.6	26
718	SNP variants at the MAP3K1/SETD9 locus 5q11.2 associate with somatic PIK3CA variants in breast cancers. European Journal of Human Genetics, 2017, 25, 384-387.	1.4	7
719	DNA damage repair in breast cancer and its therapeutic implications. Pathology, 2017, 49, 156-165.	0.3	47
720	Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. Cancer Research, 2017, 77, 790-801.	0.4	96
721	Molecular classification of breast cancer: what the pathologist needs to know. Pathology, 2017, 49, 111-119.	0.3	83
722	Tissue disruption increases stochastic gene expression thus producing tumors: Cancer initiation without driver mutation. International Journal of Cancer, 2017, 140, 2408-2413.	2.3	23
723	Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy. Molecular Pharmaceutics, 2017, 14, 4551-4559.	2.3	30
724	Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. Nature Communications, 2017, 8, 1221.	5.8	75
725	Mapping genomic and transcriptomic alterations spatially in epithelial cells adjacent to human breast carcinoma. Nature Communications, 2017, 8, 1245.	5.8	14
726	Sample Size Calculation for Differential Expression Analysis of RNA-Seq Data. , 2017, , 359-379.		0
728	Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families. Breast Cancer Research and Treatment, 2017, 166, 937-949.	1.1	16
729	Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Molecular Cancer Therapeutics, 2017, 16, 2849-2861.	1.9	41
730	Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nature Communications, 2017, 8, 268.	5.8	277
731	Identifying DNase I hypersensitive sites as driver distal regulatory elements in breast cancer. Nature Communications, 2017, 8, 436.	5.8	22
732	Mutations of RNA splicing factors in hematological malignancies. Cancer Letters, 2017, 409, 1-8.	3.2	14
733	Misregulation of Histone Methylation Regulators in Cancer. Cancer Drug Discovery and Development, 2017, , 221-248.	0.2	2
734	The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. American Journal of Pathology, 2017, 187, 2185-2198.	1.9	17

#	ARTICLE	IF	CITATIONS
735	Breast Cancer Molecular Stratification. American Journal of Pathology, 2017, 187, 2152-2162.	1.9	198
736	Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. Scientific Reports, 2017, 7, 595.	1.6	22
737	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. Scientific Reports, 2017, 7, 5995.	1.6	25
738	Machine Learning-Assisted Network Inference Approach to Identify a New Class of Genes that Coordinate the Functionality of Cancer Networks. Scientific Reports, 2017, 7, 6993.	1.6	37
739	Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers. Breast Cancer Research and Treatment, 2017, 166, 179-184.	1.1	6
740	Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer Cell, 2017, 32, 169-184.e7.	7.7	534
741	Resistance to Targeted Therapies in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2017,, .	0.1	1
742	JNK Promotes Epithelial Cell Anoikis by Transcriptional and Post-translational Regulation of BH3-Only Proteins. Cell Reports, 2017, 21, 1910-1921.	2.9	29
743	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nature Communications, 2017, 8, 1315.	5.8	228
744	Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma. Human Pathology, 2017, 70, 129-138.	1.1	12
745	Breast Cancer Genomics. , 2017,, 149-156.		0
746	Mouse Models of Breast Cancer: Deceptions that Reveal the Truth. , 2017,, 49-60.		0
747	Targeting PI3K/AKT/mTOR Pathway. , 2017,, 787-793.		0
748	Predicting treatment resistance and relapse through circulating DNA. Breast, 2017, 34, S31-S35.	0.9	17
749	Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treatment Reviews, 2017, 59, 22-32.	3.4	38
750	A novel network regularized matrix decomposition method to detect mutated cancer genes in tumour samples with inter-patient heterogeneity. Scientific Reports, 2017, 7, 2855.	1.6	10
751	Transcriptome profiling of cancer and normal tissues from cervical squamous cancer patients by deep sequencing. Molecular Medicine Reports, 2017, 16, 2075-2088.	1.1	17
752	p27 Kip1 and human cancers: A reappraisal of a still enigmatic protein. Cancer Letters, 2017, 403, 354-365.	3.2	69

#	ARTICLE	IF	CITATIONS
753	Breast cancer milestones 2007â€“2016. Memo - Magazine of European Medical Oncology, 2017, 10, 27-32.	0.3	0
754	Intratumoral heterogeneity and subclonal diversification of early breast cancer. Breast, 2017, 34, S36-S42.	0.9	15
755	Recurrent and functional regulatory mutations in breast cancer. Nature, 2017, 547, 55-60.	13.7	269
756	ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. Genome Medicine, 2017, 9, 59.	3.6	44
757	Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs. Journal of Hematology and Oncology, 2017, 10, 89.	6.9	60
758	The NF1 somatic mutational landscape in sporadic human cancers. Human Genomics, 2017, 11, 13.	1.4	203
759	Research needs in breast cancer. Annals of Oncology, 2017, 28, 208-217.	0.6	64
760	Common breast cancer risk alleles and risk assessment: a study on 35Â441 individuals from the Danish general population. Annals of Oncology, 2017, 28, 175-181.	0.6	6
761	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. Annual Review of Cancer Biology, 2017, 1, 223-240.	2.3	20
762	TP53 Mutations in Breast and Ovarian Cancer. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026252.	2.9	116
763	From Mfd to TRCF and Back Againâ€”A Perspective on Bacterial Transcriptionâ€”coupled Nucleotide Excision Repair. Photochemistry and Photobiology, 2017, 93, 268-279.	1.3	10
764	Health risk evaluation in a population exposed to chemical releases from a petrochemical complex in Thailand. Environmental Research, 2017, 152, 207-213.	3.7	23
765	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. Clinical Cancer Research, 2017, 23, 2584-2592.	3.2	15
766	Pathology and Molecular Pathology of Breast Cancer. , 2017, , 173-231.		1
767	Bioinformatics exploration of PAK1 (P21-activated kinase-1) revealed potential network gene elements in breast invasive carcinoma. Journal of Biomolecular Structure and Dynamics, 2017, 35, 2269-2279.	2.0	7
768	Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy. Seminars in Cancer Biology, 2017, 42, 13-19.	4.3	54
769	Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer. Advances in Experimental Medicine and Biology, 2017, 1026, 59-104.	0.8	46
770	Preclinical and clinical development of neoantigen vaccines. Annals of Oncology, 2017, 28, xii11-xii17.	0.6	160

#	ARTICLE	IF	CITATIONS
771	Breast Cancer: From Transcriptional Control to Clinical Outcome. , 2017, , .		1
772	Mutation Clusters from Cancer Exome. Genes, 2017, 8, 201.	1.0	1
773	Copy Number Profiling of MammaPrintâ„¢ Genes Reveals Association with the Prognosis of Breast Cancer Patients. Journal of Breast Cancer, 2017, 20, 246.	0.8	17
774	Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3KÎ±-selective Inhibitors in Breast Cancer. Theranostics, 2017, 7, 974-986.	4.6	12
775	Transcription Factors in Breast Cancerâ€”Lessons From Recent Genomic Analyses and Therapeutic Implications. Advances in Protein Chemistry and Structural Biology, 2017, 107, 223-273.	1.0	14
776	Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. Genes, 2017, 8, 217.	1.0	24
777	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. International Journal of Molecular Sciences, 2017, 18, 308.	1.8	353
778	Tumor Heterogeneity in Breast Cancer. Frontiers in Medicine, 2017, 4, 227.	1.2	379
779	Cancer Is to Embryology as Mutation Is to Genetics: Hypothesis of the Cancer as Embryological Phenomenon. Scientific World Journal, The, 2017, 2017, 1-17.	0.8	36
780	Nifedipine stimulates proliferation and migration of different breast cancer cells by distinct pathways. Molecular Medicine Reports, 2017, 16, 2259-2263.	1.1	13
781	Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients. PLoS ONE, 2017, 12, e0174022.	1.1	12
782	Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency. PLoS Genetics, 2017, 13, e1006853.	1.5	39
783	Addressing the challenges of applying precision oncology. Npj Precision Oncology, 2017, 1, 28.	2.3	43
784	A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. Cancer Convergence, 2017, 1, 5.	8.0	50
785	Characterization of potential driver mutations involved in human breast cancer by computational approaches. Oncotarget, 2017, 8, 50252-50272.	0.8	50
786	Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities. Theranostics, 2017, 7, 1088-1099.	4.6	101
787	Mutation Clusters from Cancer Exome. SSRN Electronic Journal, 0, , .	0.4	0
788	Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2â€™Targeted Therapy. JCO Precision Oncology, 2017, 1, 1-9.	1.5	0

#	ARTICLE	IF	CITATIONS
789	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. <i>Oncotarget</i> , 2017, 8, 99223-99236.	0.8	9
790	Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 3065-3074.	0.8	349
791	Identification and analysis of mutational hotspots in oncogenes and tumour suppressors. <i>Oncotarget</i> , 2017, 8, 21290-21304.	0.8	23
792	PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation. <i>Investigational New Drugs</i> , 2018, 36, 763-772.	1.2	9
793	Sequencing a super multiple synchronous lung cancer reveals a novel variant in driver gene ARID1B. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, e185-e191.	0.4	8
794	Genetic variation in sensitivity to estrogens and breast cancer risk. <i>Mammalian Genome</i> , 2018, 29, 24-37.	1.0	20
795	Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 2537-2555.	2.4	26
796	Mutational signatures of DNA mismatch repair deficiency in <i>C. elegans</i> and human cancers. <i>Genome Research</i> , 2018, 28, 666-675.	2.4	112
797	An epi(c)genetic war: Pathogens, cancer and human genome. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 333-345.	3.3	10
798	Mechanisms of Resistance to PI3K and AKT Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 117-146.	0.1	3
799	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018, 173, 371-385.e18.	13.5	1,670
800	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002279.	0.5	21
801	Bioimpedimetric analysis in conjunction with growth dynamics to differentiate aggressiveness of cancer cells. <i>Scientific Reports</i> , 2018, 8, 783.	1.6	35
802	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774604.	1.4	11
803	Biochemical Basis of APOBEC3 Deoxycytidine Deaminase Activity on Diverse DNA Substrates. <i>ACS Infectious Diseases</i> , 2018, 4, 224-238.	1.8	38
804	Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology. <i>Journal of Pathology</i> , 2018, 244, 460-468.	2.1	31
805	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 848-859.	1.2	55
806	Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2018, 20, 815-826.	1.2	57

#	ARTICLE	IF	CITATIONS
807	Nuclear receptors in cancer – uncovering new and evolving roles through genomic analysis. <i>Nature Reviews Genetics</i> , 2018, 19, 160-174.	7.7	74
808	Breast cancer: The translation of big genomic data to cancer precision medicine. <i>Cancer Science</i> , 2018, 109, 497-506.	1.7	92
809	JUNB governs a feed-forward network of TGF β ² signaling that aggravates breast cancer invasion. <i>Nucleic Acids Research</i> , 2018, 46, 1180-1195.	6.5	77
810	Non-canonical roles of PFKFB3 in regulation of cell cycle through binding to CDK4. <i>Oncogene</i> , 2018, 37, 1685-1698.	2.6	45
811	Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). <i>BMC Cancer</i> , 2018, 18, 174.	1.1	22
812	Breast cancer intratumour heterogeneity: current status and clinical implications. <i>Histopathology</i> , 2018, 73, 717-731.	1.6	50
813	High-Dimensional Phenotyping Identifies Age-Emergent Cells in Human Mammary Epithelia. <i>Cell Reports</i> , 2018, 23, 1205-1219.	2.9	39
814	Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis. <i>European Journal of Human Genetics</i> , 2018, 26, 1083-1093.	1.4	30
815	<i>CDKN2A</i> loss and <i>PIK3CA</i> mutation in myoepithelial-like metaplastic breast cancer. <i>Journal of Pathology</i> , 2018, 245, 373-383.	2.1	28
817	Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 351-360.	1.1	5
818	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. <i>British Journal of Cancer</i> , 2018, 118, 1107-1114.	2.9	26
819	High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1025-1035.	1.2	32
820	Intranuclear and higher-order chromatin organization of the major histone gene cluster in breast cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1278-1290.	2.0	40
821	Mutation screening of 10 cancer susceptibility genes in unselected breast cancer patients. <i>Clinical Genetics</i> , 2018, 93, 41-51.	1.0	15
822	Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack. <i>International Journal of Cancer</i> , 2018, 142, 7-17.	2.3	32
824	Regulation and Dysregulation of Chromosome Structure in Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 21-40.	2.3	26
825	Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers. <i>Pathobiology</i> , 2018, 85, 146-154.	1.9	33
826	A system for detecting high impact-low frequency mutations in primary tumors and metastases. <i>Oncogene</i> , 2018, 37, 185-196.	2.6	21

#	ARTICLE	IF	CITATIONS
827	Genome-Wide Transcriptome Analysis of Estrogen Receptor-Positive and Human Epithelial Growth Factor Receptor 2-Positive Breast Cancers by Ribonucleic Acid Sequencing. <i>Gynecologic and Obstetric Investigation</i> , 2018, 83, 338-348.	0.7	1
828	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2018, 8, 354-369.	7.7	62
829	MicroRNAs Change the Landscape of Cancer Resistance. <i>Methods in Molecular Biology</i> , 2018, 1699, 83-89.	0.4	7
830	Insights from structures of cancer-relevant pre-mRNA splicing factors. <i>Current Opinion in Genetics and Development</i> , 2018, 48, 57-66.	1.5	16
831	Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis. <i>Breast Cancer</i> , 2018, 25, 206-212.	1.3	41
832	Coexisting genomic aberrations associated with lymph node metastasis in breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 2310-2324.	3.9	22
833	Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. <i>Oncology Reports</i> , 2019, 41, 801-810.	1.2	76
834	ASCO 2018 highlights: metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 276-279.	0.3	14
835	USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors. <i>Molecular Cell</i> , 2018, 72, 925-941.e4.	4.5	99
836	Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?. <i>Cancers</i> , 2018, 10, 506.	1.7	40
837	De Novo Myelodysplastic Syndrome and Subsequent Diagnosis of Primary Solid Tumors: Evidence from the National Cancer Institute 2001-2011. <i>Anticancer Research</i> , 2018, 38, 5819-5823.	0.5	1
838	Validation of a next-generation sequencing oncology panel optimized for low input DNA. <i>Cancer Genetics</i> , 2018, 228-229, 55-63.	0.2	6
839	Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. <i>ACS Nano</i> , 2018, 12, 11041-11061.	7.3	200
840	Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. <i>Oncotarget</i> , 2018, 9, 17589-17596.	0.8	4
841	Personalised medicine and population health: breast and ovarian cancer. <i>Human Genetics</i> , 2018, 137, 769-778.	1.8	36
842	Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. <i>Nature Communications</i> , 2018, 9, 4181.	5.8	77
843	A novel somatic mutation of SIN3A detected in breast cancer by whole-exome sequencing enhances cell proliferation through ER α expression. <i>Scientific Reports</i> , 2018, 8, 16000.	1.6	18
844	Somatic and Germline Mutation Periodicity Follow the Orientation of the DNA Minor Groove around Nucleosomes. <i>Cell</i> , 2018, 175, 1074-1087.e18.	13.5	103

#	ARTICLE	IF	CITATIONS
845	Prognostic value of DKK2 from the Dickkopf family in human breast cancer. International Journal of Oncology, 2018, 53, 2555-2565.	1.4	6
846	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	7.7	633
847	The prognostic effects of somatic mutations in ER-positive breast cancer. Nature Communications, 2018, 9, 3476.	5.8	89
848	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nature Communications, 2018, 9, 3501.	5.8	45
849	NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. Npj Breast Cancer, 2018, 4, 29.	2.3	42
850	Cyclin-dependent kinase 1 (CDK1) and CDK2 have opposing roles in regulating interactions of splicing factor 3B1 with chromatin. Journal of Biological Chemistry, 2018, 293, 10220-10234.	1.6	15
851	Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment. Radiology, 2018, 287, 732-747.	3.6	203
852	Molecular Biology of Breast Cancer. , 2018, , 569-588.		6
853	The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation. ELife, 2018, 7, .	2.8	28
854	Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells. ELife, 2018, 7, .	2.8	20
855	Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. Anticancer Research, 2018, 38, 4435-4441.	0.5	29
856	Semi-Supervised Generative Adversarial Network for Gene Expression Inference. , 2018, , .		24
857	Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors. Frontiers in Endocrinology, 2018, 9, 393.	1.5	26
858	Applying Expression Profile Similarity for Discovery of Patient-Specific Functional Mutations. High-Throughput, 2018, 7, 6.	4.4	3
859	Tumour growth and immune evasion as targets for a new strategy in advanced cancer. Endocrine-Related Cancer, 2018, 25, R577-R604.	1.6	27
860	Impact of Genomics on Personalization of Breast Cancer Care. , 2018, , 331-372.		2
861	A characterization of postzygotic mutations identified in monozygotic twins. Human Mutation, 2018, 39, 1393-1401.	1.1	12
862	Prediction of acute myeloid leukaemia risk in healthy individuals. Nature, 2018, 559, 400-404.	13.7	617

#	ARTICLE	IF	CITATIONS
863	FGF Family: From Drug Development to Clinical Application. International Journal of Molecular Sciences, 2018, 19, 1875.	1.8	110
864	Therapeutic landscape in mutational triple negative breast cancer. Molecular Cancer, 2018, 17, 99.	7.9	70
865	Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis. Molecular Therapy - Nucleic Acids, 2018, 12, 490-503.	2.3	36
866	The oncogenic potentials and diagnostic significance of long non-coding RNA LINC00310 in breast cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 4486-4495.	1.6	21
867	Effects of FGFR1 Gene Polymorphisms on the Risk of Breast Cancer and FGFR1 Protein Expression. Cellular Physiology and Biochemistry, 2018, 47, 2569-2578.	1.1	10
868	Targeting epigenetics using synthetic lethality in precision medicine. Cellular and Molecular Life Sciences, 2018, 75, 3381-3392.	2.4	8
869	The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer. Hormones and Cancer, 2018, 9, 215-228.	4.9	36
870	New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology, 2018, 8, 258.	1.3	14
871	Gene editing in the context of an increasingly complex genome. BMC Genomics, 2018, 19, 595.	1.2	8
872	Alternative splicing in prostate cancer. Nature Reviews Clinical Oncology, 2018, 15, 663-675.	12.5	142
873	Basal-like Breast Cancers: From Pathology to Biology and Back Again. Stem Cell Reports, 2018, 10, 1676-1686.	2.3	25
874	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. JAMA Oncology, 2018, 4, 1335.	3.4	36
875	A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Computational Biology, 2018, 14, e1005965.	1.5	191
876	Modeling three-dimensional genomic organization in evolution and pathogenesis. Seminars in Cell and Developmental Biology, 2019, 90, 78-93.	2.3	10
877	Whole-Genome Sequencing in Cancer. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034579.	2.9	38
878	Unraveling the role of low-frequency mutated genes in breast cancer. Bioinformatics, 2019, 35, 36-46.	1.8	13
880	The LINC complex, mechanotransduction, and mesenchymal stem cell function and fate. Journal of Biological Engineering, 2019, 13, 68.	2.0	91
881	Estimation of joint directed acyclic graphs with lasso family for gene networks. Communications in Statistics Part B: Simulation and Computation, 2021, 50, 2793-2807.	0.6	1

#	ARTICLE	IF	CITATIONS
882	Alternative mRNA splicing in cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2019, 19, 675-687.	10.6	169
883	A Spontaneous Aggressive ER ⁺ Mammary Tumor Model Is Driven by Kras Activation. <i>Cell Reports</i> , 2019, 28, 1526-1537.e4.	2.9	19
884	Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes. <i>Nature Communications</i> , 2019, 10, 2983.	5.8	58
885	Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology. <i>Cancers</i> , 2019, 11, 1019.	1.7	28
886	Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. <i>Translational Research</i> , 2019, 212, 89-103.	2.2	47
887	Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 68.	1.3	9
888	Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer. <i>Nature Communications</i> , 2019, 10, 2860.	5.8	18
889	Targeting DNA repair in breast cancer. <i>Breast</i> , 2019, 47, 33-42.	0.9	11
890	PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer. <i>Cancers</i> , 2019, 11, 1566.	1.7	7
891	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 111.	6.9	93
892	Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 194440.	0.9	16
894	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K inhibitors. <i>Science</i> , 2019, 366, 714-723.	6.0	185
895	Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters. <i>Cancers</i> , 2019, 11, 1595.	1.7	53
896	Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491986848.	0.6	15
897	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1556.	3.4	62
898	Breast Cancer Heterogeneity in Primary and Metastatic Disease. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1152, 75-104.	0.8	27
899	Identification of cancer prognosis-associated lncRNAs based on the miRNA-TF co-regulatory motifs and dosage sensitivity. <i>Molecular Omics</i> , 2019, 15, 361-373.	1.4	3
900	Available and emerging molecular markers in the clinical management of breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 919-928.	1.5	9

#	ARTICLE	IF	CITATIONS
901	PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. <i>Cancers</i> , 2019, 11, 1318.	1.7	61
902	Tumour-specific Causal Inference Discovers Distinct Disease Mechanisms Underlying Cancer Subtypes. <i>Scientific Reports</i> , 2019, 9, 13225.	1.6	3
903	Cancer Genetics and Therapeutics. , 2019, , .		6
904	Somatic <i>SF3B1</i> mutations in myelodysplastic syndrome with ring sideroblasts and chronic lymphocytic leukaemia. <i>Journal of Clinical Pathology</i> , 2019, 72, 778-782.	1.0	17
905	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 31.	2.3	31
906	Bioinformatics Workflows for Genomic Variant Discovery, Interpretation and Prioritization. , 0, , .		3
907	Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer. <i>Science Signaling</i> , 2019, 12, .	1.6	26
908	Elephant APOBEC3A cytidine deaminase induces massive double-stranded DNA breaks and apoptosis. <i>Scientific Reports</i> , 2019, 9, 728.	1.6	4
909	The oncogenic roles of TRPM ion channels in cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 14556-14573.	2.0	18
910	A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. <i>Breast Cancer Research</i> , 2019, 21, 18.	2.2	37
911	B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. <i>Oncogene</i> , 2019, 38, 1324-1339.	2.6	10
912	Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. <i>Nature Communications</i> , 2019, 10, 2674.	5.8	240
913	Chromosome 12p Amplification in Triple-Negative/ <i>BRCA1</i> -Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. <i>Cancer Research</i> , 2019, 79, 4258-4270.	0.4	17
914	PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1. <i>Scientific Reports</i> , 2019, 9, 8755.	1.6	16
915	<p></p>Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC<p></p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4931-4946.	0.9	27
916	GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2019, 24, 271-284.	1.0	3
917	Tumor mutational profile of triple negative breast cancer patients in Thailand revealed distinctive genetic alteration in chromatin remodeling gene. <i>PeerJ</i> , 2019, 7, e6501.	0.9	18
918	Endocrine Resistance in Hormone Receptor Positive Breast Cancer—From Mechanism to Therapy. <i>Frontiers in Endocrinology</i> , 2019, 10, 245.	1.5	150

#	ARTICLE	IF	CITATIONS
919	Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer. <i>BMC Cancer</i> , 2019, 19, 465.	1.1	13
920	The significance of gene mutations across eight major cancer types. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 781, 88-99.	2.4	15
921	Aberrant alternative splicing in breast cancer. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 920-929.	1.5	67
922	Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	0.6	8
923	Assessment of the expression pattern of mTOR-associated lncRNAs and their genomic variants in the patients with breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 22044-22056.	2.0	18
924	Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update. <i>Diagnostic Cytopathology</i> , 2019, 47, 912-917.	0.5	6
925	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
926	Maximizing Polyphenol Content to Uncork the Relationship Between Wine and Cancer. <i>Frontiers in Nutrition</i> , 2019, 6, 44.	1.6	14
927	Adaptively Weighted and Robust Mathematical Programming for the Discovery of Driver Gene Sets in Cancers. <i>Scientific Reports</i> , 2019, 9, 5959.	1.6	6
928	Emerging strategies to target the dysfunctional cohesin complex in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 525-537.	1.5	12
929	Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 195-206.	1.0	13
930	The DNA damage induced by the Cytosine Deaminase APOBEC3A Leads to the production of ROS. <i>Scientific Reports</i> , 2019, 9, 4714.	1.6	10
931	OTOR in breast carcinoma as a potent prognostic predictor correlates with cell proliferation, migration, and invasiveness. <i>Biochemistry and Cell Biology</i> , 2019, 97, 750-757.	0.9	3
932	The BAF complex in development and disease. <i>Epigenetics and Chromatin</i> , 2019, 12, 19.	1.8	155
934	Upregulated expression of AT-rich interactive domain-containing protein 1B predicts poor prognosis in patients with triple-negative breast cancer. <i>Oncology Letters</i> , 2019, 17, 3289-3295.	0.8	5
935	Computational algorithms for in silico profiling of activating mutations in cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 2663-2679.	2.4	11
936	Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. <i>Nature Communications</i> , 2019, 10, 1398.	5.8	35
937	Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. <i>Journal of Clinical Oncology</i> , 2019, 37, 1148-1150.	0.8	17

#	ARTICLE	IF	CITATIONS
938	Tissue-Specific Oncogenic Activity of KRASA146T. <i>Cancer Discovery</i> , 2019, 9, 738-755.	7.7	127
939	Peptide vaccines in early breast cancer. <i>Breast</i> , 2019, 44, 128-134.	0.9	12
940	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. <i>Nature Communications</i> , 2019, 10, 620.	5.8	60
941	Patterns of Genomic Instability in Breast Cancer. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 198-211.	4.0	68
942	Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. <i>Haematologica</i> , 2019, 104, 1440-1450.	1.7	67
943	Splicing and cancer: Challenges and opportunities. <i>Wiley Interdisciplinary Reviews RNA</i> , 2019, 10, e1527.	3.2	40
944	Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1235-1242.	1.2	14
945	Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-26.	1.5	2
946	Defining Signatures of Arm-Wise Copy Number Change and Their Associated Drivers in Kidney Cancers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5762.	1.8	8
947	Mouse APOBEC1 cytidine deaminase can induce somatic mutations in chromosomal DNA. <i>BMC Genomics</i> , 2019, 20, 858.	1.2	7
948	Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1124.	1.3	52
949	JNK-Dependent cJun Phosphorylation Mitigates TGF β 2- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses. <i>Cells</i> , 2019, 8, 1481.	1.8	11
950	Deletion of tetraspanin CD151 alters the Wnt oncogene-induced mammary tumorigenesis: A cell type-linked function and signaling. <i>Neoplasia</i> , 2019, 21, 1151-1163.	2.3	14
951	Distinct functions of AKT isoforms in breast cancer: a comprehensive review. <i>Cell Communication and Signaling</i> , 2019, 17, 154.	2.7	192
952	The MS-lincRNA landscape reveals a novel lincRNA BCLIN25 that contributes to tumorigenesis by upregulating ERBB2 expression via epigenetic modification and RNA-RNA interactions in breast cancer. <i>Cell Death and Disease</i> , 2019, 10, 920.	2.7	11
953	CBNA: A control theory based method for identifying coding and non-coding cancer drivers. <i>PLoS Computational Biology</i> , 2019, 15, e1007538.	1.5	22
954	Adenomyoepitheliomas of the Breast Frequently Harbor Recurrent Hotspot Mutations in PIK3-AKT Pathway-related Genes and a Subset Show Genetic Similarity to Salivary Gland Epithelial-Myoepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2019, 43, 1005-1013.	2.1	23
955	Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	0

#	ARTICLE	IF	CITATIONS
956	Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	7
957	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. <i>Molecular Cancer Research</i> , 2019, 17, 97-108.	1.5	17
958	Genomic Applications in Breast Carcinoma. , 2019, , 347-361.		0
959	RIPK1 and Caspase-8 Ensure Chromosome Stability Independently of Their Role in Cell Death and Inflammation. <i>Molecular Cell</i> , 2019, 73, 413-428.e7.	4.5	50
960	Explore Genomic Profiles for Triple-Negative Breast Cancer to Discover Drug Targets. , 2019, , 423-440.		0
961	The T197A Knock-in Model of <i>Cdkn1b</i> Gene to Study the Effects of p27 Restoration <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2019, 18, 482-493.	1.9	2
962	Recent advances in breast cancer research impacting clinical diagnostic practice. <i>Journal of Pathology</i> , 2019, 247, 552-562.	2.1	24
963	Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study. <i>PLoS ONE</i> , 2019, 14, e0210372.	1.1	12
964	Fibroblast growth factor receptors as treatment targets in clinical oncology. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 105-122.	12.5	227
965	<i>CRTC</i> – <i>MAML2</i> fusion in mucoepidermoid carcinoma of the breast. <i>Histopathology</i> , 2019, 74, 463-473.	1.6	33
966	Evolution of Our Understanding of the Hyperparathyroid Syndromes: A Historical Perspective. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 22-37.	3.1	23
967	Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 25-39.	1.3	31
968	A survey and evaluation of Web-based tools/databases for variant analysis of TCGA data. <i>Briefings in Bioinformatics</i> , 2019, 20, 1524-1541.	3.2	48
969	Tandem RNA isolation reveals functional rearrangement of RNA-binding proteins on <i>CDKN1B/p27</i> ³ UTRs in cisplatin treated cells. <i>RNA Biology</i> , 2020, 17, 33-46.	1.5	11
970	COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 47-56.	1.1	51
971	GATA factor transcriptional activity: Insights from genome-wide binding profiles. <i>IUBMB Life</i> , 2020, 72, 10-26.	1.5	16
972	Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. <i>Clinical Cancer Research</i> , 2020, 26, 608-622.	3.2	71
973	The anaphase-promoting complex: A key mitotic regulator associated with somatic mutations occurring in cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 189-202.	1.5	12

#	ARTICLE	IF	CITATIONS
974	The roles and regulation of TBX3 in development and disease. <i>Gene</i> , 2020, 726, 144223.	1.0	51
975	Cancer-associated missense mutations enhance the pluripotency reprogramming activity of OCT4 and SOX17. <i>FEBS Journal</i> , 2020, 287, 122-144.	2.2	11
976	Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. <i>Modern Pathology</i> , 2020, 33, 1092-1103.	2.9	18
977	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020, 14, 504-519.	2.1	23
978	Functional Screening of Candidate Causal Genes for Insulin Resistance in Human Preadipocytes and Adipocytes. <i>Circulation Research</i> , 2020, 126, 330-346.	2.0	49
979	The discovery of potent and stable short peptide FGFR1 antagonist for cancer therapy. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 143, 105179.	1.9	1
980	Molecular Classification of Breast Cancer. <i>Advances in Anatomic Pathology</i> , 2020, 27, 27-35.	2.4	283
981	TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development. <i>Genes and Development</i> , 2020, 34, 179-193.	2.7	35
982	PhyDOSE: Design of follow-up single-cell sequencing experiments of tumors. <i>PLoS Computational Biology</i> , 2020, 16, e1008240.	1.5	1
983	The role of alternative splicing in cancer: From oncogenesis to drug resistance. <i>Drug Resistance Updates</i> , 2020, 53, 100728.	6.5	118
984	Effect of ABC transporter expression and mutational status on survival rates of cancer patients. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110718.	2.5	21
985	CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 2062.	2.2	45
986	Single-nucleotide polymorphism of the DNA cytosine deaminase APOBEC3H haplotype I leads to enzyme destabilization and correlates with lung cancer. <i>NAR Cancer</i> , 2020, 2, zcaa023.	1.6	13
987	Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity. <i>Trends in Cancer</i> , 2020, 6, 454-461.	3.8	15
988	Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. <i>Communications Biology</i> , 2020, 3, 578.	2.0	20
989	Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer. <i>Genome Medicine</i> , 2020, 12, 85.	3.6	39
990	Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing. <i>Scientific Reports</i> , 2020, 10, 16774.	1.6	6
992	Targeted sequencing of crucial cancer causing genes of breast cancer in Saudi patients. <i>Saudi Journal of Biological Sciences</i> , 2020, 27, 2651-2659.	1.8	4

#	ARTICLE	IF	CITATIONS
993	A Pilot Study for the Feasibility of Exome-Sequencing in Circulating Tumor Cells Versus Single Metastatic Biopsies in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 4826.	1.8	7
994	Structural and conformational changes induced by missense variants in the zinc finger domains of GATA3 involved in breast cancer. RSC Advances, 2020, 10, 39640-39653.	1.7	8
995	The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives. Seminars in Cancer Biology, 2022, 82, 35-59.	4.3	31
996	Breast Cancer Heterogeneity and Response to Novel Therapeutics. Cancers, 2020, 12, 3271.	1.7	40
997	Comparative assessments of indel annotations in healthy and cancer genomes with next-generation sequencing data. BMC Medical Genomics, 2020, 13, 170.	0.7	5
998	Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. Frontiers in Oncology, 2020, 10, 1195.	1.3	94
999	Comprehensive Cohort Analysis of Mutational Spectrum in Early Onset Breast Cancer Patients. Cancers, 2020, 12, 2089.	1.7	9
1000	The transcription factor CBFB mutations indicate an improved survival in HR+/HER2- breast cancer. Gene, 2020, 759, 144970.	1.0	5
1001	Molecular biology of breast cancer. , 2020, , 449-461.		0
1002	ARG1 functions as a tumor suppressor in breast cancer. Acta Biochimica Et Biophysica Sinica, 2020, 52, 1257-1264.	0.9	7
1003	Stage-specific protein-domain mutational profile of invasive ductal breast cancer. BMC Medical Genomics, 2020, 13, 150.	0.7	0
1004	Application of BERT to Enable Gene Classification Based on Clinical Evidence. BioMed Research International, 2020, 2020, 1-13.	0.9	8
1005	<p><Elevated Expression of ASXL2 is Associated with Poor Prognosis in Colorectal Cancer by Enhancing Tumorigenesis and Inducing Cell Proliferation</p>. Cancer Management and Research, 2020, Volume 12, 10221-10228.	0.9	4
1006	Molecular Profiles of Breast Cancer in a Single Institution. Anticancer Research, 2020, 40, 4567-4570.	0.5	2
1007	Phenotypic drift in metastatic progression of breast cancer: A case report with histologically heterogeneous lesions that are clonally related. Clinical Case Reports (discontinued), 2020, 8, 2725-2731.	0.2	1
1008	Genomic Signatures in Luminal Breast Cancer. Breast Care, 2020, 15, 355-365.	0.8	20
1009	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell, 2020, 38, 534-550.e9.	7.7	67
1010	Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer. Cancer Research, 2020, 80, 4791-4804.	0.4	15

#	ARTICLE	IF	CITATIONS
1011	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 311-324.	1.1	10
1012	The biological function and clinical significance of SF3B1 mutations in cancer. <i>Biomarker Research</i> , 2020, 8, 38.	2.8	47
1013	Transcriptomic analysis of peripheral blood mononuclear cells in head and neck squamous cell carcinoma patients. <i>Oral Diseases</i> , 2021, 27, 1394-1402.	1.5	2
1014	Co-Immobilization of Ce6 Sono/Photosensitizer and Protonated Graphitic Carbon Nitride on PCL/Gelatin Fibrous Scaffolds for Combined Sono-Photodynamic Cancer Therapy. <i>ACS Applied Materials & Interfaces</i> , 2020, 12, 40728-40739.	4.0	37
1015	Association of an anaplastic lymphoma kinase pathway signature with cell differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer. <i>Cancer Communications</i> , 2020, 40, 422-434.	3.7	6
1016	Involvement of the MEN1 Gene in Hormone-Related Cancers: Clues from Molecular Studies, Mouse Models, and Patient Investigations. <i>Endocrines</i> , 2020, 1, 58-81.	0.4	2
1017	Multi-Omics Analysis Detects Novel Prognostic Subgroups of Breast Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 574661.	1.1	18
1018	Defining the clinical genomic landscape for real-world precision oncology. <i>Genomics</i> , 2020, 112, 5324-5330.	1.3	16
1019	The effect of interleukin 10 polymorphisms on breast cancer susceptibility in Han women in Shaanxi Province. <i>PLoS ONE</i> , 2020, 15, e0232174.	1.1	8
1020	Genomic landscape of platinum resistant and sensitive testicular cancers. <i>Nature Communications</i> , 2020, 11, 2189.	5.8	43
1021	Frequency and spectrum of PIK3CA somatic mutations in breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 45.	2.2	175
1022	Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA. <i>Thoracic Cancer</i> , 2020, 11, 1861-1868.	0.8	8
1023	Identification of prognostic alternative splicing signatures in hepatitis B or/and C viruses related hepatocellular carcinoma. <i>Genomics</i> , 2020, 112, 3396-3406.	1.3	6
1024	Structure, Function, and Regulation of the SRMS Tyrosine Kinase. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4233.	1.8	10
1025	The genomic profile of parathyroid carcinoma based on whole-genome sequencing. <i>International Journal of Cancer</i> , 2020, 147, 2446-2457.	2.3	27
1026	Tumor-Cell Macrophage Fusion Cells as Liquid Biomarkers and Tumor Enhancers in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1872.	1.8	52
1027	Applying bioethical principles for directing investment in precision medicine. <i>Clinical Ethics</i> , 2020, 15, 23-28.	0.5	3
1028	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72

#	ARTICLE	IF	CITATIONS
1029	The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression. <i>Frontiers in Oncology</i> , 2020, 10, 1022.	1.3	31
1030	Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1023.	1.3	22
1031	Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer. <i>Oncolimmunology</i> , 2020, 9, 1788252.	2.1	20
1032	Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 321-332.	1.1	6
1033	Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy. <i>Advanced Therapeutics</i> , 2020, 3, 1900100.	1.6	25
1034	Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 7-22.	0.4	5
1035	Impact of mutations in DNA methylation modification genes on genome-wide methylation landscapes and downstream gene activations in pan-cancer. <i>BMC Medical Genomics</i> , 2020, 13, 27.	0.7	17
1036	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system. <i>Oncolimmunology</i> , 2020, 9, 1724049.	2.1	12
1037	Aberrant WNT/CTNNB1 Signaling as a Therapeutic Target in Human Breast Cancer: Weighing the Evidence. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 25.	1.8	66
1038	Ret Receptor Has Distinct Alterations and Functions in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2020, 25, 13-26.	1.0	12
1039	Omics Approaches to Explore the Breast Cancer Landscape. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 395.	1.8	39
1040	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. <i>Nature Genetics</i> , 2020, 52, 198-207.	9.4	140
1041	Germline Variants in Driver Genes of Breast Cancer and Their Association with Familial and Early-Onset Breast Cancer Risk in a Chilean Population. <i>Cancers</i> , 2020, 12, 249.	1.7	4
1042	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. <i>Nature Communications</i> , 2020, 11, 139.	5.8	44
1043	Next generation sequencing can be helpful in histologic diagnosis: A case report of metastatic breast cancer mimicking atypical carcinoid tumor of lung. <i>Pathology Research and Practice</i> , 2020, 216, 152835.	1.0	0
1044	Transcriptome Analysis Reveals Key Genes and Pathways Associated with Metastasis in Breast Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 323-335.	1.0	19
1045	Epigenetic Control of a Local Chromatin Landscape. <i>International Journal of Molecular Sciences</i> , 2020, 21, 943.	1.8	15
1046	TGF β 2 and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness. <i>Oncogene</i> , 2020, 39, 4436-4449.	2.6	52

#	ARTICLE	IF	CITATIONS
1047	ESOâ€“ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Annals of Oncology, 2020, 31, 674-696.	0.6	172
1048	Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients. Journal of Advanced Research, 2020, 24, 149-157.	4.4	13
1049	Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. Cancers, 2020, 12, 848.	1.7	14
1050	Genetics and Genomics of Breast Cancer: update and translational perspectives. Seminars in Cancer Biology, 2021, 72, 27-35.	4.3	14
1051	New Advances in Molecular Breast Cancer Pathology. Seminars in Cancer Biology, 2021, 72, 102-113.	4.3	37
1052	<scp><i>CDKN1B</i></scp> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. Journal of Pathology, 2021, 253, 234-245.	2.1	12
1053	Expression pattern, regulation, and clinical significance of TOX in breast cancer. Cancer Immunology, Immunotherapy, 2021, 70, 349-363.	2.0	13
1054	Evidence for Increased Susceptibility to Breast Cancer From Exposure to Ionizing Radiation Due to a Familial History of Breast Cancer: Results From the Swedish Hemangioma Cohort. American Journal of Epidemiology, 2021, 190, 76-84.	1.6	9
1055	RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. Leukemia, 2021, 35, 1053-1063.	3.3	17
1056	RNA in cancer. Nature Reviews Cancer, 2021, 21, 22-36.	12.8	655
1057	Insulin-Induced Gene 2 Expression Is Associated with Breast Cancer Metastasis. American Journal of Pathology, 2021, 191, 385-395.	1.9	2
1058	Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development. Seminars in Cancer Biology, 2021, 73, 58-75.	4.3	25
1059	A cancerâ€“associated <i>CDKN1B</i> mutation induces p27 phosphorylation on a novel residue: a new mechanism for tumor suppressor lossâ€“ofâ€“function. Molecular Oncology, 2021, 15, 915-941.	2.1	11
1060	Landscape of clinically actionable mutations in breast cancer â€“A cohort studyâ€“™. Translational Oncology, 2021, 14, 100877.	1.7	4
1061	Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer. Seminars in Cancer Biology, 2021, 72, 65-75.	4.3	33
1062	Computational methods for cancer driver discovery: A survey. Theranostics, 2021, 11, 5553-5568.	4.6	19
1063	3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 847-859.	0.4	7
1065	Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer. Oncotarget, 2021, 12, 2318-2319.	0.8	1

#	ARTICLE	IF	CITATIONS
1066	p66ShcA potentiates the cytotoxic response of triple negative breast cancers to PARP inhibitors. JCI Insight, 2021, 6, .	2.3	0
1067	Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers, 2021, 13, 521.	1.7	5
1068	Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death and Differentiation, 2021, 28, 606-625.	5.0	66
1069	CDKN1B (p27) defects leading to pituitary tumors. , 2021, , 157-172.		0
1070	TET2 is a component of the estrogen receptor complex and controls 5mC to 5hmC conversion at estrogen receptor cis-regulatory regions. Cell Reports, 2021, 34, 108776.	2.9	20
1071	Dual inhibition of TGF β 2 and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Medical Oncology, 2021, 38, 24.	1.2	7
1072	Identification of novel cell glycolysis related gene signature predicting survival in patients with breast cancer. Scientific Reports, 2021, 11, 3986.	1.6	12
1073	Identifying Breast Cancer-induced Gene Perturbations and its Application in Guiding Drug Repurposing. Current Bioinformatics, 2021, 15, 1075-1089.	0.7	12
1074	Distinct Somatic Alteration Features Identified by Gene Panel Sequencing in Korean Triple-Negative Breast Cancer with High Ki67 Expression. Diagnostics, 2021, 11, 416.	1.3	0
1075	Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study. BMC Cancer, 2021, 21, 260.	1.1	4
1076	GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature. Diagnostics, 2021, 11, 604.	1.3	12
1077	Immunotherapy as a partner for HER2-directed therapies. Expert Review of Anticancer Therapy, 2021, 21, 739-746.	1.1	5
1079	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3243-3252.	3.2	14
1080	Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs. Frontiers in Veterinary Science, 2021, 8, 664718.	0.9	21
1081	TRPS1 drives heterochromatic origin refiring and cancer genome evolution. Cell Reports, 2021, 34, 108814.	2.9	13
1082	6-lncRNA Assessment Model for Monitoring and Prognosis of HER2-Positive Breast Cancer: Based on Transcriptome Data. Pathology and Oncology Research, 2021, 27, 609083.	0.9	6
1083	Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing. Cancer Management and Research, 2021, Volume 13, 3303-3316.	0.9	5
1084	Chromatin Regulator SPEN/SHARP in X Inactivation and Disease. Cancers, 2021, 13, 1665.	1.7	5

#	ARTICLE	IF	CITATIONS
1085	The Context-Dependent Impact of Integrin-Associated CD151 and Other Tetraspanins on Cancer Development and Progression: A Class of Versatile Mediators of Cellular Function and Signaling, Tumorigenesis and Metastasis. <i>Cancers</i> , 2021, 13, 2005.	1.7	9
1086	Mutational profile of ZBTB16-positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 3839-3847.	1.3	9
1087	Deep Large-Scale Multitask Learning Network for Gene Expression Inference. <i>Journal of Computational Biology</i> , 2021, 28, 485-500.	0.8	1
1088	Making Sense of Genetic Information: The Promising Evolution of Clinical Stratification and Precision Oncology Using Machine Learning. <i>Genes</i> , 2021, 12, 722.	1.0	6
1089	Signatures of Discriminative Copy Number Aberrations in 31 Cancer Subtypes. <i>Frontiers in Genetics</i> , 2021, 12, 654887.	1.1	6
1090	Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. <i>Genome Medicine</i> , 2021, 13, 89.	3.6	10
1091	Transcription Factors: The Fulcrum Between Cell Development and Carcinogenesis. <i>Frontiers in Oncology</i> , 2021, 11, 681377.	1.3	25
1092	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. <i>Npj Breast Cancer</i> , 2021, 7, 73.	2.3	2
1093	Cohesin mutations in myeloid malignancies. <i>Blood</i> , 2021, 138, 649-661.	0.6	22
1094	DIVIS: Integrated and Customizable Pipeline for Cancer Genome Sequencing Analysis and Interpretation. <i>Frontiers in Oncology</i> , 2021, 11, 672597.	1.3	0
1095	Clinical utility of whole-genome sequencing in precision oncology. <i>Seminars in Cancer Biology</i> , 2022, 84, 32-39.	4.3	35
1096	Porcine pancreatic ductal epithelial cells transformed with KRASG12D and SV40T are tumorigenic. <i>Scientific Reports</i> , 2021, 11, 13436.	1.6	5
1097	Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families. <i>Journal of Personalized Medicine</i> , 2021, 11, 548.	1.1	4
1099	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
1100	Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. <i>Communications Biology</i> , 2021, 4, 862.	2.0	5
1101	miRNome and Functional Network Analysis of PGRMC1 Regulated miRNA Target Genes Identify Pathways and Biological Functions Associated With Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 710337.	1.3	3
1102	Uncovering the Subtype-Specific Molecular Characteristics of Breast Cancer by Multiomics Analysis of Prognosis-Associated Genes, Driver Genes, Signaling Pathways, and Immune Activity. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 689028.	1.8	14
1103	Akt Isoforms: A Family Affair in Breast Cancer. <i>Cancers</i> , 2021, 13, 3445.	1.7	31

#	ARTICLE	IF	CITATIONS
1104	A systematic view of computational methods for identifying driver genes based on somatic mutation data. Briefings in Functional Genomics, 2021, 20, 333-343.	1.3	4
1105	Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency. Oncogene, 2021, 40, 5468-5481.	2.6	12
1106	rs73092672 allele T is significantly associated with the higher risk of breast cancer incidence. Nucleosides, Nucleotides and Nucleic Acids, 2021, 40, 779-789.	0.4	1
1107	Mutational signatures: emerging concepts, caveats and clinical applications. Nature Reviews Cancer, 2021, 21, 619-637.	12.8	128
1108	Performance Comparisons of AlexNet and GoogLeNet in Cell Growth Inhibition IC50 Prediction. International Journal of Molecular Sciences, 2021, 22, 7721.	1.8	9
1109	p27Kip1, an Intrinsically Unstructured Protein with Scaffold Properties. Cells, 2021, 10, 2254.	1.8	17
1110	NCAPG promotes the progression of lung adenocarcinoma via the TGF- β 2 signaling pathway. Cancer Cell International, 2021, 21, 443.	1.8	22
1111	A Four-Genes-Based Risk Score With High Prognostic Value in Gastric Cancer. Frontiers in Oncology, 2021, 11, 584213.	1.3	6
1112	RNA-binding proteins of COSMIC importance in cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	15
1113	Frame-shifted APOBEC3A encodes two alternative proapoptotic proteins that target the mitochondrial network. Journal of Biological Chemistry, 2021, 297, 101081.	1.6	2
1114	NCOR1 Sustains Colorectal Cancer Cell Growth and Protects against Cellular Senescence. Cancers, 2021, 13, 4414.	1.7	5
1116	Diagnosis, biology and epidemiology of oligometastatic breast cancer. Breast, 2021, 59, 144-156.	0.9	6
1117	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science, 2021, 374, eabf2911.	6.0	37
1118	A protein interaction landscape of breast cancer. Science, 2021, 374, eabf3066.	6.0	66
1119	Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck. Oral Oncology, 2021, 121, 105436.	0.8	3
1120	Cellular Indoctrination: How the Tumor Microenvironment Reeducates Macrophages Towards Nefarious Ends. , 2021, , .		0
1121	An Integrated Human Mammary Epithelial Cell Culture System for Studying Carcinogenesis and Aging. , 2013, , 323-361.		22
1122	Deep Large-Scale Multi-task Learning Network for Gene Expression Inference. Lecture Notes in Computer Science, 2020, , 19-36.	1.0	4

#	ARTICLE	IF	CITATIONS
1123	Future Paradigm of Breast Cancer Resistance and Treatment. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 155-178.	0.1	2
1124	Metronomic Chemotherapy in Breast Cancers. , 2014, , 93-110.		2
1125	TGF- β^2 as Tumor Suppressor: Lessons from Mouse Models. , 2013, , 139-168.		2
1126	Molecular Profiling of Breast Cancer in Clinical Trials: A Perspective. , 2020, , 313-332.		4
1127	Systems Biology and Integrated Computational Methods for Cancer-Associated Mutation Analysis. , 2020, , 335-362.		3
1128	Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer. , 2015, 72, 4369.		1
1129	Somatic mutations of triple-negative breast cancer: a comparison between Black and White women. Breast Cancer Research and Treatment, 2020, 182, 503-509.	1.1	11
1130	Expanding the landscape of actionable genomic alterations in metastatic breast cancer: comprehensive genomic profiling for all?. Annals of Oncology, 2020, 31, 967-969.	0.6	3
1132	The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nature Communications, 2020, 11, 6433.	5.8	37
1133	Identification of cancer driver genes based on nucleotide context. Nature Genetics, 2020, 52, 208-218.	9.4	170
1134	The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead. Open Biology, 2020, 10, 200188.	1.5	27
1141	Association of APOBEC3 deletion with cancer risk: A meta-analysis of 26,225 cases and 37,201 controls. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 275-287.	0.7	8
1142	Pan-Cancer Analyses of the Nuclear Receptor Superfamily. Nuclear Receptor Research, 2015, 2, .	2.5	40
1143	Breast Cancer beyond the Age of Mutation. Gerontology, 2016, 62, 434-442.	1.4	42
1144	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. Journal of Clinical Investigation, 2019, 129, 4708-4723.	3.9	41
1145	Whole exome sequencing of adenoid cystic carcinoma. Journal of Clinical Investigation, 2013, 123, 2965-2968.	3.9	233
1146	Role of steroid receptor and coregulator mutations in hormone-dependent cancers. Journal of Clinical Investigation, 2017, 127, 1126-1135.	3.9	42
1147	Translating Genomic Research into Clinical Practice: Promise and Pitfalls. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 15-23.	1.8	7

#	ARTICLE	IF	CITATIONS
1148	Identification of Apolipoprotein C-I Peptides as a Potential Biomarker and its Biological Roles in Breast Cancer. Medical Science Monitor, 2016, 22, 1152-1160.	0.5	32
1149	Non-canonical Activation of Akt in Serum-Stimulated Fibroblasts, Revealed by Comparative Modeling of Pathway Dynamics. PLoS Computational Biology, 2015, 11, e1004505.	1.5	7
1150	Automated deconvolution of structured mixtures from heterogeneous tumor genomic data. PLoS Computational Biology, 2017, 13, e1005815.	1.5	8
1151	Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genetics, 2016, 12, e1006279.	1.5	43
1152	Somatic Mutation Patterns in Hemizygous Genomic Regions Unveil Purifying Selection during Tumor Evolution. PLoS Genetics, 2016, 12, e1006506.	1.5	24
1153	Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. PLoS Medicine, 2020, 17, e1003363.	3.9	18
1154	Heterogeneity of Gene Expression in Murine Squamous Cell Carcinoma Developmentâ€”The Same Tumor by Different Means. PLoS ONE, 2013, 8, e57748.	1.1	9
1155	The Relative Timing of Mutations in a Breast Cancer Genome. PLoS ONE, 2013, 8, e64991.	1.1	22
1156	Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts. PLoS ONE, 2013, 8, e73484.	1.1	41
1157	Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. PLoS ONE, 2013, 8, e76496.	1.1	16
1158	The Landscape of Candidate Driver Genes Differs between Male and Female Breast Cancer. PLoS ONE, 2013, 8, e78299.	1.1	46
1159	Transcriptional Repressor Tbx3 Is Required for the Hormone-Sensing Cell Lineage in Mammary Epithelium. PLoS ONE, 2014, 9, e110191.	1.1	13
1160	Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN. PLoS ONE, 2015, 10, e0126371.	1.1	28
1161	Evaluation of Two Highly-Multiplexed Custom Panels for Massively Parallel Semiconductor Sequencing on Paraffin DNA. PLoS ONE, 2015, 10, e0128818.	1.1	13
1162	Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors. PLoS ONE, 2015, 10, e0142487.	1.1	15
1163	Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance. PLoS ONE, 2016, 11, e0155840.	1.1	20
1164	Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers. PLoS ONE, 2016, 11, e0158259.	1.1	16
1165	Mutant PIK3CA Induces EMT in a Cell Type Specific Manner. PLoS ONE, 2016, 11, e0167064.	1.1	5

#	ARTICLE	IF	CITATIONS
1166	Expression of APOBEC3B mRNA in Primary Breast Cancer of Japanese Women. PLoS ONE, 2016, 11, e0168090.	1.1	17
1167	Identification of Post-Transcriptional Modulators of Breast Cancer Transcription Factor Activity Using MINDy. PLoS ONE, 2016, 11, e0168770.	1.1	4
1168	P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis. PLoS ONE, 2017, 12, e0170302.	1.1	5
1169	TFDP3 Regulates Epithelial-Mesenchymal Transition in Breast Cancer. PLoS ONE, 2017, 12, e0170573.	1.1	5
1170	Genomic sequencing identifies a few mutations driving the independent origin of primary liver tumors in a chronic hepatitis murine model. PLoS ONE, 2017, 12, e0187551.	1.1	1
1171	Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors. PLoS ONE, 2018, 13, e0194790.	1.1	3
1172	Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. PLoS ONE, 2018, 13, e0194913.	1.1	9
1173	Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis. PLoS ONE, 2020, 15, e0241924.	1.1	7
1174	Competing Risks in Low-Risk Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 32-39.	1.8	3
1175	Expression of DNA cytosine deaminase APOBEC3 proteins, a potential source for producing mutations, in gastric, colorectal and prostate cancers. Tumori, 2014, 100, 112e-7e.	0.6	7
1176	The Emerging Role of p27 in Development of Diseases. Cancer Studies and Molecular Medicine: Open Journal, 2018, 4, e1-e2.	0.5	8
1177	The Immunobiology of Cancer: An Update Review. Indonesian Biomedical Journal, 2017, 9, 53.	0.2	2
1178	Integrated <i>in vivo</i> genetic and pharmacologic screening identifies co-inhibition of EGFR and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget, 2016, 7, 42859-42872.	0.8	10
1179	The mitotic tensegrity guardian tau protects mammary epithelia from katanin-like1-induced aneuploidy. Oncotarget, 2016, 7, 53712-53734.	0.8	5
1180	Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. Oncotarget, 2016, 7, 56864-56875.	0.8	53
1181	Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. Oncotarget, 2017, 8, 66901-66911.	0.8	40
1182	Association mining of mutated cancer genes in different clinical stages across 11 cancer types. Oncotarget, 2016, 7, 68270-68277.	0.8	9
1183	p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms. Oncotarget, 2016, 7, 64560-64574.	0.8	5

#	ARTICLE	IF	CITATIONS
1184	APOBEC3 deletion increases the risk of breast cancer: a meta-analysis. Oncotarget, 2016, 7, 74979-74986.	0.8	11
1185	Somatic alterations of targetable oncogenes are frequently observed in <i>BRCA1/2</i> mutation negative male breast cancers. Oncotarget, 2016, 7, 74097-74106.	0.8	8
1186	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget, 2016, 7, 79428-79441.	0.8	11
1187	The nuclear corepressor 1 and the thyroid hormone receptor β^2 suppress breast tumor lymphangiogenesis. Oncotarget, 2016, 7, 78971-78984.	0.8	15
1188	Integrated analysis of promoter methylation and expression of telomere related genes in breast cancer. Oncotarget, 2017, 8, 25442-25454.	0.8	15
1189	A potentially functional variant of ARID1B interacts with physical activity in association with risk of hepatocellular carcinoma. Oncotarget, 2017, 8, 31057-31064.	0.8	5
1190	TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.. Oncotarget, 2014, 5, 1609-1620.	0.8	37
1191	Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. Oncotarget, 2014, 5, 1185-1197.	0.8	17
1192	Integrated analysis of dosage effect lncRNAs in lung adenocarcinoma based on comprehensive network. Oncotarget, 2017, 8, 71430-71446.	0.8	17
1193	The <i>NF1</i> gene revisited - from bench to bedside. Oncotarget, 2014, 5, 5873-5892.	0.8	139
1194	A core program of gene expression characterizes cancer metastases. Oncotarget, 2017, 8, 102161-102175.	0.8	19
1195	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget, 2014, 5, 9952-9965.	0.8	58
1196	Functional significance of co-occurring mutations in <i>PIK3CA</i> and <i>MAP3K1</i> in breast cancer. Oncotarget, 2018, 9, 21444-21458.	0.8	39
1197	Somatic mutations in early onset luminal breast cancer. Oncotarget, 2018, 9, 22460-22479.	0.8	25
1198	APOBEC3B gene expression as a novel predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer. Oncotarget, 2018, 9, 30513-30526.	0.8	6
1199	Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment. Oncotarget, 2018, 9, 35394-35407.	0.8	6
1200	Splicing regulatory factors in breast cancer hallmarks and disease progression. Oncotarget, 2019, 10, 6021-6037.	0.8	19
1201	Differential gene expression analysis of HNSCC tumors deciphered tobacco dependent and independent molecular signatures. Oncotarget, 2019, 10, 6168-6183.	0.8	18

#	ARTICLE	IF	CITATIONS
1202	Genomic differences between pure ductal carcinoma <i>in situ</i> and synchronous ductal carcinoma <i>in situ</i> with invasive breast cancer. <i>Oncotarget</i> , 2015, 6, 7597-7607.	0.8	67
1203	Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes. <i>Oncotarget</i> , 2015, 6, 9018-9030.	0.8	19
1204	Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6. <i>Oncotarget</i> , 2015, 6, 37965-37978.	0.8	35
1205	Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing. <i>Oncotarget</i> , 2015, 6, 37169-37184.	0.8	25
1206	Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. <i>Oncotarget</i> , 2013, 4, 29-34.	0.8	36
1207	microRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13. <i>Oncotarget</i> , 2016, 7, 16409-16419.	0.8	25
1208	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016, 7, 22543-22555.	0.8	11
1209	Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. <i>Oncotarget</i> , 2016, 7, 17301-17313.	0.8	22
1210	Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. <i>Oncotarget</i> , 2016, 7, 36138-36153.	0.8	6
1211	Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	11
1212	Network rewiring, adaptive resistance and combating strategies in breast cancer. , 2019, 2, 1106-1126.		5
1213	Tissue specificity of DNA damage response and tumorigenesis. <i>Cancer Biology and Medicine</i> , 2019, 16, 396-414.	1.4	32
1214	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1603-1603.	0.7	8
1215	Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. <i>Annals of Translational Medicine</i> , 2019, 7, 179-179.	0.7	56
1216	Therapeutic Targeting of Cancers with Loss of PTEN Function. <i>Current Drug Targets</i> , 2014, 15, 65-79.	1.0	194
1217	Macrophage Flipping from Foe to Friend: A Matter of Interest in Breast Carcinoma Heterogeneity Driving Drug Resistance. <i>Current Cancer Drug Targets</i> , 2019, 19, 189-198.	0.8	7
1218	Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review. <i>Current Drug Discovery Technologies</i> , 2013, 10, 147-154.	0.6	10
1219	Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 2173-2183.	0.5	41

#	ARTICLE	IF	CITATIONS
1220	Effectiveness of Teach-Back Self-Management Training Program on Happiness of Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2016, 17, 4555-4561.	0.5	13
1221	Mediator kinase module and human tumorigenesis. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 393-426.	2.3	88
1222	Radiogenomics of breast cancer as new vector of interdisciplinary integration of radiation and molecular biological technologies (literature review). Medical Alphabet, 2020, , 21-29.	0.0	3
1223	Revealing the Complexity of Breast Cancer by Next Generation Sequencing. Cancers, 2015, 7, 2183-2200.	1.7	28
1224	Evaluation of the TRPM protein family as potential biomarkers for various types of human cancer using public database analyses. Experimental and Therapeutic Medicine, 2020, 20, 770-785.	0.8	5
1225	Circulating tumor cells and breast cancer-specific mutations in primary breast cancer. Molecular and Clinical Oncology, 2020, 12, 565-573.	0.4	4
1226	Screening of the prognostic targets for breast cancer based co-expression modules analysis. Molecular Medicine Reports, 2017, 16, 4038-4044.	1.1	20
1227	ZW10 interacting kinetochore protein may serve as a prognostic biomarker for human breast cancer: An integrated bioinformatics analysis. Oncology Letters, 2020, 19, 2163-2174.	0.8	12
1228	Long non-coding RNA NPBWR1-2 affects the development of ovarian cancer via multiple microRNAs. Oncology Letters, 2020, 20, 685-692.	0.8	2
1229	Many Breast Cancer Mutations Parallel Mutations in Known Viral Cancers. Journal of Genomes and Exomes, 0, 3, 17-35.	0.0	2
1230	Tumor-Dependent and -Independent Serum/Plasma Biomarkers for Early Diagnosis of Lung Cancer. Translational Medicine (Sunnyvale, Calif), 2016, 06, .	0.4	5
1231	Holistic cancer genome profiling for every patient. Swiss Medical Weekly, 2020, 150, w20158.	0.8	5
1232	Cohesin gene mutations in tumorigenesis: from discovery to clinical significance. BMB Reports, 2014, 47, 299-310.	1.1	55
1233	Sure Independence Screening Adjusted for Confounding Covariates with Ultrahigh-dimensional Data. Statistica Sinica, 2017, , .	0.2	3
1234	Common Variants in the PALB2 Gene Confer Susceptibility to Breast Cancer: a Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7149-7154.	0.5	9
1235	Preventive and Risk Reduction Strategies for Women at High Risk of Developing Breast Cancer: a Review. Asian Pacific Journal of Cancer Prevention, 2016, 17, 895-904.	0.5	7
1236	Translational genomics in cancer research: converting profiles into personalized cancer medicine. Cancer Biology and Medicine, 2013, 10, 214-20.	1.4	10
1237	Repair of naturally occurring mismatches can induce mutations in flanking DNA. ELife, 2014, 3, e02001.	2.8	80

#	ARTICLE	IF	CITATIONS
1238	5-hydroxymethylcytosine marks regions with reduced mutation frequency in human DNA. ELife, 2016, 5, .	2.8	28
1239	The Single-Cell Sequencing: A Dazzling Light Shining on the Dark Corner of Cancer. Frontiers in Oncology, 2021, 11, 759894.	1.3	1
1240	Comprehensive Analysis of Ferroptosis-Related LncRNAs in Breast Cancer Patients Reveals Prognostic Value and Relationship With Tumor Immune Microenvironment. Frontiers in Surgery, 2021, 8, 742360.	0.6	17
1241	The Role of Emerin in Cancer Progression and Metastasis. International Journal of Molecular Sciences, 2021, 22, 11289.	1.8	15
1242	An Introduction to Molecular Pathology. , 2002, , 15-36.		0
1244	Translating Genomic Research into Clinical Practice: Promise and Pitfalls. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 15-23.	1.8	4
1247	Omics Technologies Applied in Breast Cancer Research. , 2014, , 3-15.		0
1248	UDP-N-Acetylglucosamine Pyrophosphorylase 1 (UAP1). , 2014, , 1503-1509.		0
1249	Are mutations in K-RAS, BRAF and PIK3CA genes critical for response to adjuvant trastuzumab treatment in patients with HER-2 positive breast cancer?. Journal of Cancer Therapeutics & Research, 2014, 3, 3.	1.2	2
1251	Next Generation Sequencing in Cancer Research and Clinical Application. , 2014, , 71-94.		1
1252	Genomic Applications in Breast Carcinoma. , 2015, , 359-382.		0
1254	Next-Generation Sequencing Applications in Head and Neck Oncology. , 2015, , 401-422.		0
1255	Molecular Pathology of Lobular Carcinoma. Molecular Pathology Library, 2015, , 95-105.	0.1	0
1259	Genomic Markers in ER-Negative Breast Cancer. , 2016, , 283-298.		0
1260	Environmental chemical exposures and breast cancer. AIMS Environmental Science, 2016, 3, 96-114.	0.7	0
1261	Alternative Splicing in Breast Cancer. , 2016, , 365-377.		0
1262	Tumor Heterogeneity in Breast Cancer. , 2016, , 121-132.		0
1263	Next-Generation Sequencing Based Testing for Breast Cancer. , 2016, , 299-328.		0

#	ARTICLE	IF	CITATIONS
1264	Biology and Genetics of Breast Cancer. , 2016, , 145-160.		1
1271	Atypical Teratoid/Rhabdoid Tumor (AT/RT). Pediatric Oncology, 2018, , 221-242.	0.5	1
1277	Endocrine Therapy of Metastatic Breast Cancer. , 2019, , 533-555.		0
1280	Beyond Synthetic Lethality: Charting the Landscape of Clinically Relevant Genetic Interactions in Cancer. SSRN Electronic Journal, 0, , .	0.4	0
1282	Insights into breast cancer phenotyping through molecular omics approaches and therapy response. , 2019, 2, 527-538.		2
1283	Biology and Genetics of Breast Cancer. , 2019, , 125-142.		0
1284	Interacciones g�nicas implicadas en la aparici�n anticipada de c�ncer de mama invasor en la poblaci�n â�paysa�. Colombia. CES Medicina, 2019, 33, 21-30.	0.1	0
1286	Comparing the Effectiveness of Acceptance and Commitment Therapy and Solution-focused Brief Therapy on Pain Catastrophizing and Psychological Well-Being of Patients With Breast Cancer. Avicenna Journal of Neuro Psycho Physiology, 0, , 27-36.	0.1	1
1289	Case Report: Sustained Complete Response to PI3K Inhibition in a Patient with Metastatic Breast Cancer Harboring PIK3CA, NF1, and CDH1 Mutations. Journal of Immunotherapy and Precision Oncology, 2020, 3, 133-136.	0.6	0
1290	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5471.	1.7	18
1291	Two oppositely-charged sf3b1 mutations cause defective development, impaired immune response, and aberrant selection of intronic branch sites in Drosophila. PLoS Genetics, 2021, 17, e1009861.	1.5	2
1293	Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology. Journal of Cancer Research Updates, 0, 9, 37-68.	0.3	0
1295	Dissecting the heterogeneity and tumorigenesis of BRCA1 deficient mammary tumors via single cell RNA sequencing. Theranostics, 2021, 11, 9967-9987.	4.6	6
1297	Hereditary : BRCA and Other. , 2020, , 23-41.		0
1298	Loss of ASXL1 expression is associated with lymph node metastasis in colorectal cancer. Indian Journal of Pathology and Microbiology, 2020, 63, 221.	0.1	6
1300	APOBEC3B expression and its prognostic potential in breast cancer. Oncology Letters, 2020, 19, 3205-3214.	0.8	7
1302	Discovery of a novel potentially transforming somatic mutation in <i>CSF2RB</i> gene in breast cancer. Cancer Medicine, 2021, 10, 8138-8150.	1.3	6
1303	APOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response. NAR Cancer, 2020, 2, zcaa033.	1.6	5

#	ARTICLE	IF	CITATIONS
1305	Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients. <i>Molecules and Cells</i> , 2018, 41, 465-475.	1.0	4
1309	A mathematical model for short-term vs. long-term survival in patients with glioma. <i>American Journal of Cancer Research</i> , 2014, 4, 862-73.	1.4	8
1311	Bi-phasic expression of Heterochromatin Protein 1 (HP1) during breast cancer progression: Potential roles of HP1 and chromatin structure in tumorigenesis. <i>Journal of Nature and Science</i> , 2015, 1, e127.	1.1	6
1312	APOBEC3 Deletion is Associated with Breast Cancer Risk in a Sample of Southeast Iranian Population. <i>International Journal of Molecular and Cellular Medicine</i> , 2015, 4, 103-8.	1.1	21
1313	Into the eye of the storm: breast cancer's somatic mutation landscape points to DNA damage and repair. <i>Translational Cancer Research</i> , 2013, 2, 59-61.	0.4	1
1314	Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. <i>Cancer Biology and Medicine</i> , 2015, 12, 316-27.	1.4	5
1315	C/EBP β inhibits proliferation of breast cancer cells via a novel pathway of miR-134/CREB. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 14472-8.	0.5	9
1317	Disease evolution and heterogeneity in bilateral breast cancer. <i>American Journal of Cancer Research</i> , 2016, 6, 2611-2630.	1.4	5
1318	Cancer Prevention and Treatment by Wholistic Nutrition. <i>Journal of Nature and Science</i> , 2017, 3, .	1.1	5
1319	, , and genetic profile in Moroccan triple negative breast cancer cases. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2020, 11, 16-25.	0.4	1
1320	Progress and assessment of lncRNA DGCR5 in malignant phenotype and immune infiltration of human cancers. <i>American Journal of Cancer Research</i> , 2021, 11, 1-13.	1.4	10
1322	Herpes Simplex Virus Type 1 Infection Disturbs the Mitochondrial Network, Leading to Type I Interferon Production through the RNA Polymerase III/RIG-I Pathway. <i>MBio</i> , 2021, 12, e0255721.	1.8	16
1323	E239K mutation abolishes the suppressive effects of lysine-specific demethylase 1 on migration and invasion of MCF7 cells. <i>Cancer Science</i> , 2022, 113, 489-499.	1.7	3
1324	Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients. <i>Annals of Translational Medicine</i> , 2021, 10, 0-0.	0.7	1
1325	Systems Biology Resources and Their Applications to Understand the Cancer. , 2021, , 1-35.		0
1327	The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. <i>Breast</i> , 2022, 61, 77-83.	0.9	38
1328	Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors. <i>Cancer Research</i> , 2022, 82, 819-830.	0.4	16
1329	The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 2: breast cancer. <i>British Dental Journal</i> , 2022, 232, 95-100.	0.3	2

#	ARTICLE	IF	CITATIONS
1330	Spectrum of MAP3K1 mutations in breast cancer is luminal subtypeâ€™predominant and related to prognosis. <i>Oncology Letters</i> , 2022, 23, 68.	0.8	5
1331	The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 797505.	1.3	4
1332	Retinoblastoma protein regulates carcinogen susceptibility at heterochromatic cancer driver loci. <i>Life Science Alliance</i> , 2022, 5, e202101134.	1.3	4
1333	Computational Prediction of the Pathogenic Status of Cancer-Specific Somatic Variants. <i>Frontiers in Genetics</i> , 2021, 12, 805656.	1.1	1
1334	Neurofibromin and suppression of tumorigenesis: beyond the GAP. <i>Oncogene</i> , 2022, 41, 1235-1251.	2.6	13
1335	Distribution of copy number variations and rearrangement endpoints in human cancers with a review of literature. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2022, 824, 111773.	0.4	6
1336	Systems Biology Resources and Their Applications to Understand the Cancer. , 2022, , 2349-2383.		0
1337	MicroRNA-367 Inhibits Breast Cancer and Promotes Apoptosis by Targeting AT-Rich Interactive Domain-Containing Protein 1B. <i>Journal of Biomaterials and Tissue Engineering</i> , 2022, 12, 717-723.	0.0	1
1338	Image Analysis of Circulating Tumor Cells and Leukocytes Predicts Survival and Metastatic Pattern in Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 725318.	1.3	3
1339	Parental histone deposition on the replicated strands promotes error-free DNA damage tolerance and regulates drug resistance. <i>Genes and Development</i> , 2022, 36, 167-179.	2.7	6
1340	Large Animal Models of Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 788038.	1.3	13
1341	RAS and beyond: the many faces of the neurofibromatosis type 1 protein. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	11
1342	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. <i>Nature Communications</i> , 2022, 13, 896.	5.8	46
1343	In silico recognition of a prognostic signature in basal-like breast cancer patients. <i>PLoS ONE</i> , 2022, 17, e0264024.	1.1	5
1344	Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	0
1346	The Role of Tumor Stem Cell Exosomes in Cancer Invasion and Metastasis. <i>Frontiers in Oncology</i> , 2022, 12, 836548.	1.3	17
1347	A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. <i>Frontiers in Oncology</i> , 2022, 12, 786438.	1.3	6
1348	Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications. <i>Seminars in Cancer Biology</i> , 2022, 86, 769-783.	4.3	36

#	ARTICLE	IF	CITATIONS
1349	Subclonal heterogeneity and evolution in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 155.	2.3	23
1350	ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. <i>Journal of the ICRU</i> , 2021, 21, 1-212.	6.0	52
1351	“Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics”™. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 783494.	1.6	6
1352	Panel Informativity Optimizer. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 697-709.	1.2	2
1353	Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 745-752.	2.3	7
1354	Systems biology of cancer progression. , 0, , 1-6.		0
1393	From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer. <i>Chinese Clinical Oncology</i> , 2014, 3, 16.	0.4	3
1395	Circulating Glycan Monosaccharide Composite-Based Biomarker Diagnoses Colorectal Cancer at Early Stages and Predicts Prognosis. <i>Frontiers in Oncology</i> , 2022, 12, 852044.	1.3	3
1396	Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. <i>Cancers</i> , 2022, 14, 2404.	1.7	2
1397	Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer. <i>Cancers</i> , 2022, 14, 2397.	1.7	1
1398	Kindlin-2 promotes Src-mediated tyrosine phosphorylation of androgen receptor and contributes to breast cancer progression. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	3
1399	Agonist/antagonist compounds' mechanism of action on estrogen receptor-positive breast cancer: A system-level investigation assisted by meta-analysis. <i>Informatics in Medicine Unlocked</i> , 2022, 31, 100985.	1.9	2
1400	ROS1 altered breast cancers “a distinctive molecular subtype of PR- metastatic breast cancers: Expanding the scope of targeted therapeutics. <i>Breast Disease</i> , 2022, 41, 295-301.	0.4	0
1401	Heritable genomic diversity in breast cancer driver genes and associations with risk in a Chilean population. <i>Biological Research</i> , 2022, 55, .	1.5	1
1402	The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. <i>Experimental and Molecular Pathology</i> , 2022, 127, 104787.	0.9	27
1404	Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. <i>Biomedicines</i> , 2022, 10, 1313.	1.4	9
1405	Mechanistic Effects of Estrogens on Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 224-240.	1.0	8
1406	Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. <i>Targeted Oncology</i> , 2022, 17, 355-368.	1.7	1

#	ARTICLE	IF	CITATIONS
1407	Breast Cancer Genomics: Primary and Most Common Metastases. <i>Cancers</i> , 2022, 14, 3046.	1.7	3
1408	MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211123.	1.0	0
1409	High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	8
1410	Multomics technologies: role in disease biomarker discoveries and therapeutics. <i>Briefings in Functional Genomics</i> , 2023, 22, 76-96.	1.3	5
1411	The role of <sc>SF3B1</sc> and <sc>NOTCH1</sc> in the pathogenesis of leukemia. <i>IUBMB Life</i> , 0, , .	1.5	1
1412	Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. <i>Nature Communications</i> , 2022, 13, .	5.8	28
1413	Biological Random Walks: multi-omics integration for disease gene prioritization. <i>Bioinformatics</i> , 2022, 38, 4145-4152.	1.8	4
1414	Sparse Bayesian Multiview Learning for Simultaneous Association Discovery and Diagnosis of Alzheimer's Disease. <i>Proceedings of the AAAI Conference on Artificial Intelligence</i> , 2015, 29, .	3.6	7
1415	Association of Pathway Mutations With Survival in Taiwanese Breast Cancers. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1416	Immunology and immunotherapy in breast cancer. <i>Cancer Biology and Medicine</i> , 2022, 19, 609-618.	1.4	10
1417	Onepot-Seq: capturing single-cell transcriptomes simultaneously in a continuous medium via transient localization of mRNA. <i>Nucleic Acids Research</i> , 0, , .	6.5	1
1418	Prevalence of Estrogen Receptor Alpha (<i>ESR1</i>) Somatic Mutations in Breast Cancer. <i>JNCI Cancer Spectrum</i> , 0, , .	1.4	0
1419	Unified classification and risk-stratification in Acute Myeloid Leukemia. <i>Nature Communications</i> , 2022, 13, .	5.8	61
1420	The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. <i>Nature Communications</i> , 2022, 13, .	5.8	22
1421	Harnessing gene fusion-derived neoantigens for "cold" breast and prostate tumor immunotherapy. <i>Immunotherapy</i> , 2022, 14, 1165-1179.	1.0	4
1422	Cell Division/Death: Cell Cycle " CDK Inhibitors in Normal and Malignant Cells. , 2022, , .		0
1423	The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. <i>Genes</i> , 2022, 13, 1555.	1.0	2
1424	ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. <i>Cell Reports</i> , 2022, 40, 111268.	2.9	5

#	ARTICLE	IF	CITATIONS
1425	TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 255-266.	1.1	3
1426	Combination of AURKA inhibitor and HSP90 inhibitor to treat breast cancer with AURKA overexpression and TP53 mutations. , 2022, 39, .		4
1427	Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1428	Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor. <i>Cell Genomics</i> , 2022, 2, 100179.	3.0	74
1429	Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1430	Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	3
1432	Role of the Histone Acetyl Transferase MOF and the Histone Deacetylase Sirtuins in Regulation of H4K16ac During DNA Damage Repair and Metabolic Programming: Implications in Cancer and Aging. <i>Sub-Cellular Biochemistry</i> , 2022, , 115-141.	1.0	0
1433	Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset. <i>Journal of Clinical Oncology</i> , 2023, 41, 766-777.	0.8	10
1434	The Predictive and Prognostic Role of RASâ€“RAFâ€“MEKâ€“ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. <i>Cancers</i> , 2022, 14, 5306.	1.7	12
1435	Core promoter in TNBC is highly mutated with rich ethnic signature. <i>Briefings in Functional Genomics</i> , 0, , .	1.3	0
1436	Geostatistical Modeling and Heterogeneity Analysis of Tumor Molecular Landscape. <i>Cancers</i> , 2022, 14, 5235.	1.7	2
1437	Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	2
1438	K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. <i>Cancers</i> , 2022, 14, 5322.	1.7	1
1439	A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13322.	1.8	2
1440	Nuclear Morphological Abnormalities in Cancer: A Search for Unifying Mechanisms. <i>Results and Problems in Cell Differentiation</i> , 2022, , 443-467.	0.2	14
1441	Molecular Mechanisms of Breast Cancer Metastasis. , 0, , .		0
1442	Understanding of â€œNetworksâ€™ In Vitro and/or In Vivo. , 2016, , 344-355.		0
1443	High SURF4 expression is associated with poor prognosis of breast cancer. <i>Aging</i> , 2022, 14, 9317-9337.	1.4	4

#	ARTICLE	IF	CITATIONS
1444	The Analysis of Relevant Gene Networks Based on Driver Genes in Breast Cancer. <i>Diagnostics</i> , 2022, 12, 2882.	1.3	2
1445	dTMP imbalance through thymidylate 5â€²-phosphohydrolase activity induces apoptosis in triple-negative breast cancers. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
1446	SETD7 Expression Is Associated with Breast Cancer Survival Outcomes for Specific Molecular Subtypes: A Systematic Analysis of Publicly Available Datasets. <i>Cancers</i> , 2022, 14, 6029.	1.7	2
1447	Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. <i>Nature Communications</i> , 2022, 13, .	5.8	5
1449	MicroRNA-dependent mechanisms of taxane resistance in breast cancer. <i>Opuholi Zenskoj Reproktivnoy Sistem</i> , 2022, 18, 52-63.	0.1	0
1450	A network-based method for identifying cancer driver genes based on node control centrality. <i>Experimental Biology and Medicine</i> , 2023, 248, 232-241.	1.1	0
1451	Multimomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. <i>Nature Cancer</i> , 0, , .	5.7	13
1452	Whole Genome Sequencing of Single-Circulating Tumor Cell Ameliorates Unraveling Breast Cancer Heterogeneity. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 14, 505-513.	1.0	0
1453	Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2288.	1.8	5
1454	HER2-driven breast cancer suppression by the JNK signaling pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	4
1456	Deciphering breast cancer: from biology to the clinic. <i>Cell</i> , 2023, 186, 1708-1728.	13.5	72
1457	Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. <i>Genome Medicine</i> , 2023, 15, .	3.6	4
1459	The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	4
1460	LRT-CLUSTER: A New Clustering Algorithm Based on Likelihood Ratio Test to Identify Driving Genes. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 0, , .	2.2	0
1461	Computer-aided drug designing illuminate polypharmacology of natural products against multiple estrogen receptor. , 2023, , 281-333.		0
1462	Correlation between ARID1B gene mutation (p.A460, p.V215G) and prognosis of high-risk refractory neuroblastoma. <i>Cell Biology International</i> , 2023, 47, 1222-1228.	1.4	2
1463	BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1464	Pathology and Somatic Alterations in Hereditary Lobular Breast Cancers. , 2023, , 167-180.		0

#	ARTICLE	IF	CITATIONS
1465	Role of T-box transcription factor 3 in gastric cancers. World Journal of Gastrointestinal Pathophysiology, 0, 14, 12-20.	0.5	0
1466	Identification of a centrosome-related prognostic signature for breast cancer. Frontiers in Oncology, 0, 13, .	1.3	3
1467	The Association between Early-Onset Diagnosis and Clinical Outcomes in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Cancers, 2023, 15, 1923.	1.7	1
1468	Advancing biomarker development for diagnostics and therapeutics using solid tumour cancer stem cell models. Tumori, 2024, 110, 10-24.	0.6	0
1469	The targeted next-generation sequence revealed SMAD4, AKT1, and TP53 mutations from circulating cell-free DNA of breast cancer and its effect on protein structure “ A computational approach. Journal of Biomolecular Structure and Dynamics, 2023, 41, 15584-15597.	2.0	0
1470	Breast Cancer: Impact of New Treatments?. Cancers, 2023, 15, 2205.	1.7	4
1474	Genomic Landscape of Breast Cancer. , 2023, , 25-40.		0
1480	Genetic and Chromosomal Instability. , 2023, , 25-44.		0
1484	Biology of breast cancer brain metastases and novel therapies targeting the blood brain barrier: an updated review. , 2023, 40, .		1
1490	Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research. Journal of Mammary Gland Biology and Neoplasia, 2023, 28, .	1.0	2
1521	Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Cancer Treatment and Research, 2023, , 219-235.	0.2	1
1533	Whole Exome Analysis to Analyse the Mutational Profiles of Taiwanese Patients with Breast Cancer. Lecture Notes in Networks and Systems, 2024, , 248-256.	0.5	0